[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 42 of about 42
1. Wang E, Lichtenfels R, Bükur J, Ngalame Y, Panelli MC, Seliger B, Marincola FM: Ontogeny and oncogenesis balance the transcriptional profile of renal cell cancer. Cancer Res; 2004 Oct 15;64(20):7279-87
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Global transcript analysis is increasingly used to describe cancer taxonomies beyond the microscopic reach of the eye.
  • We compared the transcriptional profile of primary renal cell cancers (RCCs) with that of normal kidney tissue and several epithelial cancers of nonrenal origin to weigh the contribution that ontogeny and oncogenesis make in molding their genetic profile.
  • Genes responsible for lineage specificity may represent poor molecular targets for immune or drug therapy.
  • Most genes associated with oncogenesis are shared with other cancers and may represent better therapeutic targets.
  • [MeSH-minor] Adenocarcinoma, Clear Cell / enzymology. Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / metabolism. Carbonic Anhydrases / biosynthesis. Carbonic Anhydrases / genetics. Disease Progression. Gene Expression Profiling. Glutathione Transferase / biosynthesis. Glutathione Transferase / genetics. Humans. Melanoma / genetics. Melanoma / metabolism. Multigene Family. Prognosis. Sarcoma / genetics. Sarcoma / metabolism. Transcription, Genetic

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15492247.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.5.1.18 / Glutathione Transferase; EC 4.2.1.1 / Carbonic Anhydrases
  •  go-up   go-down


2. Gray ST, Chen YL, Lin DT: Efficacy of Proton Beam Therapy in the Treatment of Ewing's Sarcoma of the Paranasal Sinuses and Anterior Skull Base. Skull Base; 2009 Nov;19(6):409-16

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of Proton Beam Therapy in the Treatment of Ewing's Sarcoma of the Paranasal Sinuses and Anterior Skull Base.
  • Ewing's sarcoma involving the sinonasal cavity and anterior skull base is very rare.
  • The purpose of this article is to present our experience with two such cases, which were both treated with combined chemotherapy and proton beam radiation therapy.
  • The patients were selected from a retrospective medical record analysis that was conducted of all patients who were diagnosed with Ewing's sarcoma of the sinonasal cavity at the Massachusetts Eye & Ear Infirmary/Massachusetts General Hospital Cranial Base Center from 2004 to 2008.
  • One of the patients underwent pretreatment endoscopic subtotal resection to facilitate proton beam radiation therapy.
  • Response to treatment was assessed, post-treatment endoscopic biopsies were performed to assure eradication of disease, and treatment complications were recorded.
  • Both patients completed chemotherapy and proton beam radiation therapy without complication.
  • One patient completed treatment in December 2006 and remains disease free.
  • The second patient completed treatment in March 2007 and remains disease free.
  • Both patients developed headaches accompanied by frontal sinus opacification after treatment that required endoscopic drainage.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2006 Jan;19(1):1-8 [16258512.001]
  • [Cites] Cancer. 1976 Nov;38(5):1925-30 [991106.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1996 Oct;105(10):838-43 [8865780.001]
  • [Cites] J Clin Oncol. 1992 Sep;10(9):1407-12 [1517783.001]
  • [Cites] Cancer. 1991 Jun 1;67(11):2818-25 [2025847.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Mar;20(3):389-95 [1995522.001]
  • [Cites] J Clin Oncol. 1990 Oct;8(10):1664-74 [2213103.001]
  • [Cites] Cancer. 1989 Apr 15;63(8):1477-86 [2924256.001]
  • [Cites] J Clin Oncol. 1989 Feb;7(2):208-13 [2915236.001]
  • [Cites] Cancer. 1988 Jan 1;61(1):23-32 [3334950.001]
  • [Cites] Cancer. 1987 Dec 1;60(11):2829-40 [3677016.001]
  • [Cites] J Clin Oncol. 1990 Sep;8(9):1514-24 [2099751.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1990 Jan;69(1):120-7 [2404224.001]
  • [Cites] Recent Results Cancer Res. 1982;80:124-7 [7058276.001]
  • [Cites] Cancer. 1981 May 1;47(9):2204-13 [7226113.001]
  • [Cites] J Bone Joint Surg Br. 1978 Nov;60-B(4):567-74 [711809.001]
  • [Cites] J Bone Joint Surg Am. 1961 Mar;43-A:185-92 [13719331.001]
  • (PMID = 20436842.001).
  • [ISSN] 1532-0065
  • [Journal-full-title] Skull base : official journal of North American Skull Base Society ... [et al.]
  • [ISO-abbreviation] Skull Base
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2793890
  • [Keywords] NOTNLM ; Ewing's sarcoma / anterior skull base / endoscopic surgery / proton beam
  •  go-up   go-down


3. Mittal R, Al Awadi S, Sahar O, Behbehani AM: Ewing's sarcoma as second malignant neoplasm after retinoblastoma: a case report. Med Princ Pract; 2008;17(1):84-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ewing's sarcoma as second malignant neoplasm after retinoblastoma: a case report.
  • OBJECTIVES: To report a case of a child with the hereditary form of unilateral retinoblastoma (RB), who developed Ewing's sarcoma of the right fibula 3 years after the enucleation of the right eye.
  • CASE PRESENTATION AND INTERVENTION: The child was diagnosed as a case of RB of the right eye at the age of 9 months.
  • The patient received chemotherapy and diode laser thermotherapy in Kuwait and the UK.
  • He had a local relapse after 11 months and subsequently underwent enucleation of the right eye.
  • After extensive investigations, it was reported as Ewing's sarcoma.
  • He was treated with chemotherapy, surgery (complete excision of the fibula) and high-dose chemotherapy followed by autologous stem cell transplantation.
  • The child is now nearly 2 years after completing the treatment and is disease free.
  • These children need a very close follow-up for the early diagnosis of SMNs or even subsequent malignancies.
  • [MeSH-major] Bone Neoplasms / diagnosis. Fibula. Neoplasms, Second Primary / diagnosis. Retinal Neoplasms / diagnosis. Retinoblastoma / diagnosis. Sarcoma, Ewing / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child, Preschool. Diagnosis, Differential. Eye Enucleation. Humans. Infant. Male. Stem Cell Transplantation. Treatment Outcome

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • Genetic Alliance. consumer health - Retinoblastoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 S. Karger AG, Basel.
  • (PMID = 18059108.001).
  • [ISSN] 1423-0151
  • [Journal-full-title] Medical principles and practice : international journal of the Kuwait University, Health Science Centre
  • [ISO-abbreviation] Med Princ Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


Advertisement
4. Raney RB, Maurer HM, Anderson JR, Andrassy RJ, Donaldson SS, Qualman SJ, Wharam MD, Wiener ES, Crist WM: The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major Lessons From the IRS-I Through IRS-IV Studies as Background for the Current IRS-V Treatment Protocols. Sarcoma; 2001;5(1):9-15
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major Lessons From the IRS-I Through IRS-IV Studies as Background for the Current IRS-V Treatment Protocols.
  • Untreated patients < 21 years of age at diagnosis received systemic chemotherapy, with or without irradiation (XRT) and/or surgical removal of the tumor.Methods.
  • Pathologic materials and treatment were reviewed to ascertain compliance and to confirm response and relapse status.Results.
  • Important lessons include the fact that extent of disease at diagnosis affects prognosis.
  • The eye, vagina, and bladder can usually be saved.
  • Patients with non-metastatic cranial parameningeal sarcoma can usually be cured with localized XRT and systemic chemotherapy, without whole-brain XRT and intrathecal drugs.
  • Mature rhabdomyoblasts after treatment of patients with bladder rhabdomyosarcoma are not necessarily malignant, provided that the tumor has shrunk and malignant cells have disappeared.Discussion.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):213-9 [11134215.001]
  • [Cites] J Pediatr Surg. 2000 Jun;35(6):961-4 [10873044.001]
  • [Cites] Science. 1990 Nov 30;250(4985):1233-8 [1978757.001]
  • [Cites] Med Pediatr Oncol. 1990;18(6):466-71 [2233517.001]
  • [Cites] J Clin Oncol. 1990 Mar;8(3):443-52 [2407808.001]
  • [Cites] J Pediatr Surg. 1989 Jan;24(1):5-10 [2723995.001]
  • [Cites] World J Surg. 1988 Oct;12(5):676-84 [3072777.001]
  • [Cites] Cancer. 1988 Jan 15;61(2):209-20 [3275486.001]
  • [Cites] J Clin Oncol. 1988 Jan;6(1):67-75 [3275751.001]
  • [Cites] J Pediatr Hematol Oncol. 1995 Nov;17(4):331-7 [7583389.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):610-30 [7884423.001]
  • [Cites] Med Pediatr Oncol. 1994;23(2):99-106 [8202048.001]
  • [Cites] J Clin Oncol. 1993 Feb;11(2):262-70 [8426203.001]
  • [Cites] Cancer. 1993 Mar 1;71(5):1904-22 [8448756.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):886-900 [8622037.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):69-75 [8996126.001]
  • [Cites] J Pediatr Hematol Oncol. 1997 Mar-Apr;19(2):124-9 [9149741.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1831-6 [9164192.001]
  • [Cites] Cancer. 1997 Sep 15;80(6):1165-70 [9305719.001]
  • [Cites] J Pediatr Hematol Oncol. 1997 Nov-Dec;19(6):483-91 [9407933.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3468-75 [10550144.001]
  • [Cites] Am J Epidemiol. 1992 Jan 15;135(2):190-9 [1536134.001]
  • (PMID = 18521303.001).
  • [ISSN] 1357-714X
  • [Journal-full-title] Sarcoma
  • [ISO-abbreviation] Sarcoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2395450
  •  go-up   go-down


5. Verma V, Shen D, Sieving PC, Chan CC: The role of infectious agents in the etiology of ocular adnexal neoplasia. Surv Ophthalmol; 2008 Jul-Aug;53(4):312-31
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By elucidating the mechanisms by which infectious agents contribute to oncogenesis, the management, treatment, and prevention of these neoplasms may one day parallel what is already in place for cancers such as cervical cancer, hepatocellular carcinoma, gastric mucosa-associated lymphoid tissue lymphoma and gastric adenocarcinoma.
  • Antibiotic treatment and vaccines against infectious agents may herald a future with a curtailed role for traditional therapies of surgery, radiation, and chemotherapy.
  • This review discusses the pathogenetic role of several microorganisms in different ocular adnexal malignancies, including human papilloma virus in conjunctival papilloma and squamous cell carcinoma, human immunodeficiency virus in conjunctival squamous carcinoma, Kaposi sarcoma-associated herpes virus or human herpes simplex virus-8 (KSHV/HHV-8) in conjunctival Kaposi sarcoma, Helicobacter pylori (H. pylori,), Chlamydia, and hepatitis C virus in ocular adnexal mucosa-associated lymphoid tissue lymphomas.
  • [MeSH-major] Eye Infections, Bacterial / microbiology. Eye Infections, Viral / virology. Eye Neoplasms / microbiology. Eye Neoplasms / virology
  • [MeSH-minor] Alphapapillomavirus / isolation & purification. Alphapapillomavirus / physiology. Carcinoma, Squamous Cell / virology. Chlamydophila psittaci / isolation & purification. Chlamydophila psittaci / physiology. Conjunctival Neoplasms / microbiology. Conjunctival Neoplasms / virology. Eyelid Neoplasms / microbiology. Eyelid Neoplasms / virology. HIV-1 / isolation & purification. HIV-1 / physiology. Helicobacter pylori / isolation & purification. Helicobacter pylori / physiology. Hepacivirus / isolation & purification. Hepacivirus / physiology. Herpesvirus 8, Human / isolation & purification. Herpesvirus 8, Human / physiology. Humans. Lacrimal Apparatus Diseases / microbiology. Lacrimal Apparatus Diseases / virology. Lymphoma, B-Cell, Marginal Zone / virology. Orbital Neoplasms / microbiology. Orbital Neoplasms / virology. Sarcoma, Kaposi / virology

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • HIV InSite. treatment guidelines - Ophthalmic Manifestations of HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Ophthalmol Scand. 2000 Dec;78(6):663-6 [11167228.001]
  • [Cites] J Virol. 2001 Feb;75(4):1857-63 [11160684.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1218-23 [11158620.001]
  • [Cites] Ophthalmology. 2001 Mar;108(3):559-62 [11237911.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] AIDS. 2001 Mar 30;15(5):629-33 [11317001.001]
  • [Cites] Ophthalmology. 2001 May;108(5):979-84 [11320031.001]
  • [Cites] Br J Cancer. 2002 Jul 29;87(3):301-8 [12177799.001]
  • [Cites] Cornea. 2002 Nov;21(8):838-9 [12410049.001]
  • [Cites] Leuk Lymphoma. 2002 Oct;43(10):1975-7 [12481895.001]
  • [Cites] Cornea. 2003 Jan;22(1):1-4 [12502938.001]
  • [Cites] N Engl J Med. 2003 Feb 6;348(6):489-90 [12571255.001]
  • [Cites] Arch Ophthalmol. 2003 Feb;121(2):280-2 [12583801.001]
  • [Cites] Carcinogenesis. 2003 Feb;24(2):159-69 [12584163.001]
  • [Cites] Ophthalmologe. 2003 Feb;100(2):142-4 [12589459.001]
  • [Cites] Cornea. 2003 Mar;22(2):135-7 [12605048.001]
  • [Cites] Acta Ophthalmol Scand. 2003 Apr;81(2):193-6 [12752062.001]
  • [Cites] Oncogene. 2003 May 29;22(22):3371-85 [12776188.001]
  • [Cites] Arch Soc Esp Oftalmol. 2003 May;78(5):265-71 [12789630.001]
  • [Cites] J Natl Cancer Inst Monogr. 2003;(31):57-65 [12807947.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):673-96, v [12852650.001]
  • [Cites] Acta Ophthalmol Scand. 2003 Aug;81(4):411-3 [12859274.001]
  • [Cites] Arch Ophthalmol. 2003 Jul;121(7):1052-3 [12860816.001]
  • [Cites] J Med Microbiol. 2003 Aug;52(Pt 8):721-6 [12867569.001]
  • [Cites] Lancet. 2003 Jul 26;362(9380):305-15 [12892963.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):865-71 [12910532.001]
  • [Cites] Ann Oncol. 2003 Sep;14(9):1341-5 [12954572.001]
  • [Cites] Cent Afr J Med. 2003 Jan-Feb;49(1-2):1-4 [14562592.001]
  • [Cites] Ophthalmology. 2004 Sep;111(9):1747-54 [15350332.001]
  • [Cites] Histol Histopathol. 2004 Oct;19(4):1219-26 [15375765.001]
  • [Cites] Cancer. 1972 Jan;29(1):252-60 [5007387.001]
  • [Cites] N Engl J Med. 1978 Nov 30;299(22):1215-20 [309554.001]
  • [Cites] Am J Ophthalmol. 1982 Apr;93(4):393-402 [6280503.001]
  • [Cites] Ann Ophthalmol. 1982 May;14(5):497-9 [7114684.001]
  • [Cites] Cancer. 1983 Oct 15;52(8):1410-6 [6193858.001]
  • [Cites] Am J Ophthalmol. 1983 Nov;96(5):670-4 [6314814.001]
  • [Cites] Ophthalmology. 1984 Sep;91(9):1092-9 [6093020.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 1985;223(3):164-7 [2993107.001]
  • [Cites] Anticancer Res. 1985 Sep-Oct;5(5):485-98 [3904595.001]
  • [Cites] Ophthalmology. 1986 Feb;93(2):176-83 [3951824.001]
  • [Cites] Arch Ophthalmol. 1986 Dec;104(12):1801-5 [3024607.001]
  • [Cites] Arch Ophthalmol. 1986 Dec;104(12):1814-5 [3024608.001]
  • [Cites] Am J Ophthalmol. 1987 Mar 15;103(3 Pt 1):294-301 [3030111.001]
  • [Cites] J Natl Cancer Inst. 1987 Oct;79(4):671-7 [2821311.001]
  • [Cites] Hum Pathol. 1987 Nov;18(11):1115-9 [2824322.001]
  • [Cites] Hum Pathol. 1988 Nov;19(11):1315-26 [3141260.001]
  • [Cites] N Engl J Med. 1989 Jun 1;320(22):1442-6 [2541337.001]
  • [Cites] Lancet. 1990 Jan 20;335(8682):123-8 [1967430.001]
  • [Cites] N Engl J Med. 1991 Oct 17;325(16):1127-31 [1891020.001]
  • [Cites] Nat Med. 1995 Dec;1(12):1274-8 [7489408.001]
  • [Cites] CA Cancer J Clin. 1996 Jan-Feb;46(1):5-27 [8548526.001]
  • [Cites] J Clin Pathol. 1995 Dec;48(12):1106-10 [8567996.001]
  • [Cites] Ophthalmology. 1996 Apr;103(4):631-5 [8618763.001]
  • [Cites] Lancet. 1996 May 25;347(9013):1450-1 [8676629.001]
  • [Cites] Am J Pathol. 1996 Jun;148(6):2009-16 [8669485.001]
  • [Cites] Nat Med. 1996 Aug;2(8):918-24 [8705863.001]
  • [Cites] Br J Ophthalmol. 1999 Jun;83(6):742-7 [10340987.001]
  • [Cites] J Natl Cancer Inst. 1999 Oct 20;91(20):1725-33 [10528022.001]
  • [Cites] Sex Transm Infect. 1999 Oct;75(5):317-9 [10616355.001]
  • [Cites] AIDS. 1999 Dec 24;13(18):2583-8 [10630528.001]
  • [Cites] J Clin Pathol. 1999 Aug;52(8):569-73 [10645225.001]
  • [Cites] Br J Ophthalmol. 2000 Mar;84(3):268-72 [10684836.001]
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2000 May;41(6):1270-9 [10798640.001]
  • [Cites] J Immunol. 2000 May 15;164(10):5522-9 [10799921.001]
  • [Cites] Nat Med. 2000 May;6(5):536-42 [10802709.001]
  • [Cites] J Biomed Sci. 2000 Sep-Oct;7(5):341-56 [10971133.001]
  • [Cites] J Med Virol. 2000 Oct;62(2):251-8 [11002256.001]
  • [Cites] Arch Ophthalmol. 1997 Nov;115(11):1464-6 [9366682.001]
  • [Cites] Gastroenterology. 1997 Dec;113(6):1848-57 [9394724.001]
  • [Cites] Gastroenterology. 1997 Dec;113(6 Suppl):S61-4 [9394762.001]
  • [Cites] Ophthalmology. 1998 Jan;105(1):185-90 [9442797.001]
  • [Cites] N Engl J Med. 1998 Feb 12;338(7):423-8 [9459645.001]
  • [Cites] Am J Respir Crit Care Med. 1998 Feb;157(2):458-63 [9476858.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2290-5 [9482878.001]
  • [Cites] Br J Ophthalmol. 1997 Nov;81(11):1019-20 [9505833.001]
  • [Cites] Annu Rev Med. 1998;49:289-99 [9509264.001]
  • [Cites] N Engl J Med. 1998 Apr 2;338(14):948-54 [9521982.001]
  • [Cites] Sex Transm Infect. 1998 Feb;74(1):32-4 [9634298.001]
  • [Cites] J Natl Cancer Inst Monogr. 1998;(23):65-71 [9709306.001]
  • [Cites] Bull Soc Belge Ophtalmol. 1998;268:135-41 [9810095.001]
  • [Cites] AIDS. 1998 Oct 22;12(15):2067-72 [9814876.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1999 Mar;40(3):555-62 [10067957.001]
  • [Cites] Gastroenterology. 1999 Apr;116(4):823-30 [10092304.001]
  • [Cites] Ophthalmology. 1999 Apr;106(4):757-60 [10201599.001]
  • [Cites] Br J Ophthalmol. 1999 Jan;83(1):98-103 [10209445.001]
  • [Cites] J Reprod Immunol. 1998 Dec;41(1-2):149-60 [10213307.001]
  • [Cites] J Vet Intern Med. 1999 May-Jun;13(3):153-62 [10357102.001]
  • [Cites] Cornea. 1999 Jul;18(4):495-7 [10422866.001]
  • [Cites] J Pathol. 1999 Sep;189(1):12-9 [10451482.001]
  • [Cites] BMJ. 1999 Aug 21;319(7208):505-8 [10454408.001]
  • [Cites] Cornea. 2001 May;20(4):427-9 [11333335.001]
  • [Cites] Br J Ophthalmol. 2001 Jul;85(7):785-7 [11423448.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1251-69 [11423257.001]
  • [Cites] Mod Pathol. 2001 Jul;14(7):641-9 [11454995.001]
  • [Cites] Dermatology. 2001;203(1):19-23 [11549794.001]
  • [Cites] CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36 [11577478.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2001 Oct;42(11):2450-7 [11581182.001]
  • [Cites] Lancet. 2001 Sep 22;358(9286):958-65 [11583749.001]
  • [Cites] Ann N Y Acad Sci. 2001 Sep;941:69-85 [11594584.001]
  • [Cites] JAMA. 2002 Jan 9;287(2):221-5 [11779265.001]
  • [Cites] Curr Opin Immunol. 2002 Feb;14(1):111-6 [11790540.001]
  • [Cites] Br J Ophthalmol. 2002 Feb;86(2):168-73 [11815342.001]
  • [Cites] Arch Ophthalmol. 2002 Feb;120(2):202-4 [11831924.001]
  • [Cites] Oncogene. 2002 Feb 14;21(8):1251-62 [11850845.001]
  • [Cites] Can J Ophthalmol. 2002 Feb;37(1):14-9; discussion 19-20 [11865953.001]
  • [Cites] Ophthalmology. 2002 Mar;109(3):542-7 [11874759.001]
  • [Cites] Adv Cancer Res. 2002;84:231-76 [11883529.001]
  • [Cites] Am J Clin Pathol. 2002 Mar;117(3):429-36 [11888082.001]
  • [Cites] J Clin Pathol. 2002 Apr;55(4):244-65 [11919208.001]
  • [Cites] Am J Ophthalmol. 2002 May;133(5):601-6 [11992855.001]
  • [Cites] Oncogene. 2002 Jun 6;21(25):3949-60 [12037677.001]
  • [Cites] Am J Ophthalmol. 2002 Aug;134(2):268-70 [12140037.001]
  • [Cites] J Virol. 2005 Dec;79(24):15027-37 [16306573.001]
  • [Cites] Ophthalmologe. 2005 Dec;102(12):1204-6 [15657692.001]
  • [Cites] Ann Oncol. 2006 Jan;17(1):135-40 [16236754.001]
  • [Cites] J Virol. 2006 Jan;80(2):697-709 [16378973.001]
  • [Cites] Blood. 2006 Jan 15;107(2):467-72 [16166588.001]
  • [Cites] Ophthalmologe. 2003 Oct;100(10):808-14 [14618353.001]
  • [Cites] Gut. 2004 Jan;53(1):34-7 [14684573.001]
  • [Cites] J Pathol. 2004 Jan;202(1):23-33 [14694518.001]
  • [Cites] Oral Oncol. 2004 Feb;40(2):120-30 [14693234.001]
  • [Cites] Curr Hematol Rep. 2004 Jan;3(1):11-6 [14695844.001]
  • [Cites] Surv Ophthalmol. 2004 Jan-Feb;49(1):3-24 [14711437.001]
  • [Cites] Gastroenterology. 2003 Dec;125(6):1723-32 [14724825.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] J Virol. 2004 Apr;78(8):4063-73 [15047823.001]
  • [Cites] J Clin Microbiol. 2004 Apr;42(4):1648-51 [15071020.001]
  • [Cites] J Natl Cancer Inst. 2004 Apr 21;96(8):586-94 [15100336.001]
  • [Cites] Ophthalmology. 2004 Jun;111(6):1233-7 [15177977.001]
  • [Cites] Croat Med J. 2004 Jun;45(3):328-32 [15185428.001]
  • [Cites] Eur J Haematol. 2004 Oct;73(4):258-62 [15347312.001]
  • [Cites] Klin Oczna. 2005;107(7-9):475-8 [16417001.001]
  • [Cites] Br J Haematol. 2006 Mar;132(5):651-2 [16445841.001]
  • [Cites] Jpn J Ophthalmol. 2006 Jan-Feb;50(1):7-11 [16453181.001]
  • [Cites] Ann Oncol. 2006 Mar;17(3):484-7 [16500916.001]
  • [Cites] Int J Surg Pathol. 2006 Jan;14(1):85-8 [16501843.001]
  • [Cites] Hematol Oncol. 2006 Mar;24(1):33-7 [16385613.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 1;98(5):365-6 [16507837.001]
  • [Cites] Virchows Arch. 2006 Mar;448(3):301-5 [16328355.001]
  • [Cites] Leuk Res. 2006 May;30(5):547-51 [16246419.001]
  • [Cites] Int J Cancer. 2006 Jun 15;118(12):3030-44 [16404738.001]
  • [Cites] J Infect Dis. 2006 May 1;193(9):1250-7 [16586362.001]
  • [Cites] Virchows Arch. 2006 Apr;448(4):506-16 [16323006.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3034-44 [16397126.001]
  • [Cites] Am J Gastroenterol. 2006 Apr;101(4):714-20 [16635219.001]
  • [Cites] Ann Oncol. 2006 May;17(5):769-72 [16524978.001]
  • [Cites] Cornea. 2006 May;25(4):490-2 [16670494.001]
  • [Cites] J Mol Histol. 2005 Sep;36(6-7):401-12 [16402152.001]
  • [Cites] Eur J Ophthalmol. 2006 May-Jun;16(3):473-7 [16761254.001]
  • [Cites] Am J Ophthalmol. 2006 Jun;141(6):1162-3 [16765702.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9220-5 [16751281.001]
  • [Cites] Br J Ophthalmol. 2006 Jul;90(7):819-22 [16672325.001]
  • [Cites] J Pathol. 2006 Jul;209(3):344-51 [16583361.001]
  • [Cites] Ann Oncol. 2006 Jun;17 Suppl 8:viii15-viii23 [16801335.001]
  • [Cites] Lancet. 1991 Nov 9;338(8776):1175-6 [1682595.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1992 Jan;33(1):184-9 [1309728.001]
  • [Cites] Br J Ophthalmol. 1992 Jan;76(1):47-8 [1739692.001]
  • [Cites] Lancet. 1992 Mar 14;339(8794):632-5 [1347337.001]
  • [Cites] J Virol. 1992 Apr;66(4):2125-34 [1312623.001]
  • [Cites] Acta Ophthalmol (Copenh). 1992 Apr;70(2):248-54 [1319099.001]
  • [Cites] Adv Exp Med Biol. 1992;321:45-9; discussion 51 [1333167.001]
  • [Cites] Ophthalmology. 1993 Apr;100(4):569-73 [8386822.001]
  • [Cites] N Engl J Med. 1994 May 5;330(18):1267-71 [8145781.001]
  • [Cites] Cancer. 1994 May 1;73(9):2395-9 [8168043.001]
  • [Cites] Radiother Oncol. 1994 Mar;30(3):263-6 [7516086.001]
  • [Cites] Am J Ophthalmol. 1994 Oct 15;118(4):463-7 [7943124.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Dec 1;30(5):1207-11 [7525519.001]
  • [Cites] J Pathol. 1994 Sep;174(1):33-7 [7965401.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Lancet. 1995 Mar 18;345(8951):695-6 [7885126.001]
  • [Cites] Lancet. 1995 Mar 25;345(8952):761-2 [7891488.001]
  • [Cites] Br J Ophthalmol. 1995 Apr;79(4):392-3 [7742294.001]
  • [Cites] Lancet. 1995 Jun 24;345(8965):1591-4 [7783535.001]
  • [Cites] J Natl Cancer Inst. 1995 Jun 7;87(11):796-802 [7791229.001]
  • [Cites] Arch Ophthalmol. 1995 Aug;113(8):978 [7639671.001]
  • [Cites] Nat Med. 1995 Jul;1(7):707-8 [7585156.001]
  • [Cites] Cancer Lett. 2006 Jul 28;239(1):98-102 [16143449.001]
  • [Cites] J Natl Cancer Inst. 2006 Jul 5;98(13):936-9 [16818858.001]
  • [Cites] Mod Pathol. 2006 Aug;19(8):1055-67 [16648871.001]
  • [Cites] East Afr Med J. 2006 May;83(5):267-70 [16866221.001]
  • [Cites] Ophthalmic Epidemiol. 2006 Aug;13(4):275-9 [16877286.001]
  • [Cites] Curr Opin Oncol. 2006 Sep;18(5):479-86 [16894296.001]
  • [Cites] Clin Cancer Res. 2006 Aug 1;12(15):4491-8 [16899594.001]
  • [Cites] Leuk Res. 2006 Oct;30(10):1305-7 [16420962.001]
  • [Cites] Viral Immunol. 2006 Summer;19(3):468-80 [16987065.001]
  • [Cites] J Natl Cancer Inst. 2006 Oct 4;98(19):1375-82 [17018784.001]
  • [Cites] J Med Microbiol. 2006 Nov;55(Pt 11):1571-5 [17030918.001]
  • [Cites] Ann Oncol. 2006 Nov;17(11):1721-2 [16760269.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11120-4 [17145854.001]
  • [Cites] Rev Med Interne. 2007 Jan;28(1):22-7 [17070619.001]
  • [Cites] Am J Surg Pathol. 2007 Feb;31(2):170-84 [17255761.001]
  • [Cites] Clin Pharmacol Ther. 2007 Feb;81(2):259-64 [17259949.001]
  • [Cites] Ann Oncol. 2007 Feb;18(2):400-1; author reply 401-3 [17065589.001]
  • [Cites] Leuk Lymphoma. 2007 Jan;48(1):104-8 [17325853.001]
  • [Cites] J Acquir Immune Defic Syndr. 2007 Mar 1;44(3):351-5 [17195763.001]
  • [Cites] Trans Am Ophthalmol Soc. 2006;104:62-70 [17471326.001]
  • [Cites] Br J Ophthalmol. 2007 Aug;91(8):1014-5 [17166894.001]
  • [Cites] Cancer Treat Res. 2007;133:185-213 [17672042.001]
  • [Cites] Leuk Res. 2007 Oct;31(10):1450-2 [17257672.001]
  • [Cites] Ophthalmology. 2007 Jan;114(1):182-6 [17198854.001]
  • [Cites] Nat Med. 1996 Aug;2(8):925-8 [8705864.001]
  • [Cites] Ann Dermatol Venereol. 1996;123(2):90-2 [8761758.001]
  • [Cites] Infect Immun. 1996 Nov;64(11):4872-5 [8890256.001]
  • [Cites] Nippon Ganka Gakkai Zasshi. 1996 Mar;100(3):246-52 [8900592.001]
  • [Cites] CA Cancer J Clin. 1997 Jan-Feb;47(1):5-27 [8996076.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997 Feb;83(2):259-64 [9117759.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Feb;6(2):73-7 [9037556.001]
  • [Cites] Ophthalmology. 1995 Dec;102(12):1994-2006 [9098307.001]
  • [Cites] Am J Ophthalmol. 1997 Apr;123(4):551-2 [9124255.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Jun;6(6):387-400 [9184771.001]
  • [Cites] Br J Ophthalmol. 1997 Apr;81(4):308-13 [9215061.001]
  • [Cites] Blood. 1997 Jul 15;90(2):776-82 [9226178.001]
  • [Cites] Aust N Z J Ophthalmol. 1997 Aug;25(3):211-5 [9296295.001]
  • [Cites] Clin Microbiol Rev. 1997 Oct;10(4):720-41 [9336670.001]
  • [Cites] J Clin Microbiol. 1999 Oct;37(10):3316-22 [10488198.001]
  • [Cites] Rev Esp Enferm Dig. 1999 Aug;91(8):541-8 [10491486.001]
  • [Cites] Am J Ophthalmol. 1999 Sep;128(3):362-4 [10511035.001]
  • [Cites] Am J Ophthalmol. 1950 Aug;33(8):1203-19 [15432557.001]
  • [Cites] Am J Clin Pathol. 2004 Dec;122(6):938-43 [15539387.001]
  • [Cites] Ann Hematol. 2005 Jan;84(1):13-8 [15309523.001]
  • [Cites] Ophthalmologe. 2004 Oct;101(10):1011-6 [15185119.001]
  • [Cites] Cytokine. 2005 Feb 21;29(4):141-52 [15652446.001]
  • [Cites] Retina. 2005 Jan;25(1):94-8 [15655452.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Am J Gastroenterol. 2005 Feb;100(2):290-4 [15667484.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):939-47 [15705894.001]
  • [Cites] Acta Dermatovenerol Croat. 2005;13(1):22-7 [15788143.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):773-8 [15824142.001]
  • [Cites] J Virol. 2005 Jul;79(13):8079-89 [15956553.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5067-73 [15968003.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2005 Jul;21(4):314-5 [16052151.001]
  • [Cites] Mol Carcinog. 2005 Oct;44(2):77-82 [16075467.001]
  • [Cites] Nat Rev Immunol. 2005 Oct;5(10):749-59 [16175180.001]
  • [Cites] Nippon Ganka Gakkai Zasshi. 2005 Sep;109(9):573-9 [16218435.001]
  • [Cites] Am J Ophthalmol. 2005 Oct;140(4):729-30 [16226528.001]
  • [Cites] Arch Dermatol. 2005 Nov;141(11):1429-34 [16301390.001]
  • (PMID = 18572051.001).
  • [ISSN] 0039-6257
  • [Journal-full-title] Survey of ophthalmology
  • [ISO-abbreviation] Surv Ophthalmol
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 EY000222-22
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] United States
  • [Number-of-references] 248
  • [Other-IDs] NLM/ NIHMS58178; NLM/ PMC2507724
  •  go-up   go-down


6. Mimeault M, Batra SK: Targeting of cancer stem/progenitor cells plus stem cell-based therapies: the ultimate hope for treating and curing aggressive and recurrent cancers. Panminerva Med; 2008 Mar;50(1):3-18
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting of cancer stem/progenitor cells plus stem cell-based therapies: the ultimate hope for treating and curing aggressive and recurrent cancers.
  • The rapid progression from aggressive primary cancers into locally advanced and invasive and/or metastatic diseases remains a big obstacle for an early diagnosis and curative therapeutic intervention for cancer patients.
  • The late-stage leukemias and disseminated and metastatic sarcomas, melanomas, brain tumors and epithelial cancers are the devastating diseases associated with a high rate of recurrence after treatment with the conventional clinical therapies including surgery, ionizing radiation, hormonal therapy and systemic chemotherapy, which generally lead to the death of patients.
  • Therefore, the establishment of the molecular events underlying cancer initiation and progression into locally invasive and metastatic diseases is of major interest in basic cancer research as well as for the development of new effective clinical therapeutic options against the recurrent and lethal cancers.
  • Of therapeutic interest, the molecular targeting of deregulated signaling elements in cancer stem/progenitor cells and their local microenvironment represents a new potential strategy for the development of more effective clinical treatments against aggressive cancers.
  • Particularly, the combined use of chemotherapeutic drugs to eradicate cancer-initiating cells with hematopoietic stem cell or genetically-modified stem cell transplant is emerging as potential cancer treatments that hold great promise in the area of clinical cancer research.
  • These targeting and stem cell-based therapies may offer the ultimate hope for treating and even curing the patients diagnosed with locally advanced cancers at high risk of recurrence, metastatic and/or relapsed cancers in the clinics.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematology Am Soc Hematol Educ Program. 2003;:82-101 [14633778.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15178-83 [14645703.001]
  • [Cites] Blood. 2004 Feb 1;103(3):1166-70 [14512297.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2332-6 [14630803.001]
  • [Cites] Cancer Lett. 2004 Feb 20;204(2):213-24 [15013220.001]
  • [Cites] Blood Rev. 2004 Sep;18(3):167-79 [15183901.001]
  • [Cites] Eur J Cancer. 2004 Jul;40(10):1522-9 [15196536.001]
  • [Cites] Crit Rev Oncol Hematol. 2004 Jul;51(1):1-28 [15207251.001]
  • [Cites] Nat Immunol. 2004 Jul;5(7):738-43 [15170211.001]
  • [Cites] Transfusion. 2004 Jul;44(7):1087-97 [15225252.001]
  • [Cites] Panminerva Med. 2004 Mar;46(1):49-59 [15238881.001]
  • [Cites] Skin Pharmacol Physiol. 2004 Jul-Aug;17(4):153-66 [15258446.001]
  • [Cites] N Engl J Med. 2004 Aug 12;351(7):657-67 [15306667.001]
  • [Cites] N Engl J Med. 2004 Sep 2;351(10):998-1012 [15342808.001]
  • [Cites] Oncogene. 2004 Sep 20;23(43):7274-82 [15378087.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14228-33 [15381773.001]
  • [Cites] Am J Pathol. 2006 Dec;169(6):2223-35 [17148683.001]
  • [Cites] Expert Opin Biol Ther. 2007 Jan;7(1):41-51 [17150018.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] Neurobiol Dis. 2007 Feb;25(2):217-29 [17141509.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1030-7 [17283135.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1113-20 [17283145.001]
  • [Cites] Stem Cells. 2007 Feb;25(2):371-9 [17038675.001]
  • [Cites] J BUON. 2006 Oct-Dec;11(4):433-8 [17309174.001]
  • [Cites] Nature. 2007 Feb 22;445(7130):851-7 [17314971.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2187-96 [17332349.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Mar;20(1):57-65 [17336255.001]
  • [Cites] J Natl Compr Canc Netw. 2007 Feb;5(2):203-15 [17335689.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4635-40 [17299092.001]
  • [Cites] Genes Dev. 2007 Jun 1;21(11):1382-95 [17510286.001]
  • [Cites] Pediatr Blood Cancer. 2007 Aug;49(2):196-8 [17417796.001]
  • [Cites] Mol Vis. 2007;13:823-32 [17615543.001]
  • [Cites] Carcinogenesis. 2007 Jul;28(7):1379-86 [17341655.001]
  • [Cites] Clin Exp Metastasis. 2007;24(5):353-62 [17487557.001]
  • [Cites] Clin Pharmacol Ther. 2007 Sep;82(3):252-64 [17671448.001]
  • [Cites] Stem Cells Dev. 2007 Aug;16(4):637-48 [17784837.001]
  • [Cites] Stem Cells. 2007 Sep;25(9):2302-11 [17569791.001]
  • [Cites] Ann Oncol. 2007 Oct;18(10):1605-19 [17355951.001]
  • [Cites] Carcinogenesis. 2007 Sep;28(9):2053-8 [17434930.001]
  • [Cites] Int J Cancer. 2007 Nov 15;121(10):2125-31 [17565741.001]
  • [Cites] Clin Exp Metastasis. 2007;24(7):485-93 [17653825.001]
  • [Cites] Pigment Cell Res. 2007 Dec;20(6):458-65 [17935489.001]
  • [Cites] Cancer Treat Rev. 2008 May;34(3):247-58 [18226859.001]
  • [Cites] Stem Cell Rev. 2008 Spring;4(1):27-49 [18288619.001]
  • [Cites] Blood. 2000 Feb 1;95(3):1007-13 [10648416.001]
  • [Cites] Blood. 2001 Aug 15;98(4):1166-73 [11493466.001]
  • [Cites] Lancet Oncol. 2002 Jan;3(1):35-43 [11905603.001]
  • [Cites] Nat Immunol. 2002 Jul;3(7):687-94 [12068293.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):442-54 [12189386.001]
  • [Cites] Cancer Cell. 2002 Sep;2(3):175-8 [12242149.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5657-63 [12384520.001]
  • [Cites] Nat Rev Cancer. 2002 Nov;2(11):826-35 [12415253.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7170-4 [12499252.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Pathol Oncol Res. 2003;9(1):13-9 [12704441.001]
  • [Cites] Growth Factors. 2003 Mar;21(1):1-14 [12795332.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):685-94 [12951587.001]
  • [Cites] Cell Mol Life Sci. 2005 Aug;62(16):1863-70 [16003493.001]
  • [Cites] Nat Rev Cancer. 2005 Sep;5(9):744-9 [16148886.001]
  • [Cites] Mini Rev Med Chem. 2005 Sep;5(9):805-24 [16178723.001]
  • [Cites] Ernst Schering Found Symp Proc. 2006;(5):155-79 [17939301.001]
  • [Cites] Oncologist. 2007 Oct;12(10):1237-46 [17962617.001]
  • [Cites] Front Biosci. 2008;13:1887-91 [17981676.001]
  • [Cites] J Cell Mol Med. 2007 Sep-Oct;11(5):981-1011 [17979879.001]
  • [Cites] Med Princ Pract. 2008;17(1):84-5 [18059108.001]
  • [Cites] Br J Hosp Med (Lond). 2007 Nov;68(11):589-93 [18087845.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2008 Feb;49(2):636-43 [18235009.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):626-32 [18235122.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Feb;5(2):102-11 [18235442.001]
  • [Cites] Nat Rev Cancer. 2006 Jun;6(6):425-36 [16723989.001]
  • [Cites] Mol Cancer Ther. 2006 May;5(5):1299-308 [16731763.001]
  • [Cites] Eur J Cancer. 2006 Jun;42(9):1309-15 [16682183.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6063-71 [16778178.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2891-6 [16782928.001]
  • [Cites] J Cell Biochem. 2006 Jul 1;98(4):757-69 [16598744.001]
  • [Cites] Hepatology. 2006 Jul;44(1):240-51 [16799977.001]
  • [Cites] Curr Drug Targets. 2006 Jul;7(7):861-79 [16842217.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9 [16849428.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7011-21 [15466194.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7445-52 [16885340.001]
  • [Cites] Leukemia. 2006 Sep;20(9):1533-8 [16871285.001]
  • [Cites] Cell Cycle. 2006 Aug;5(15):1597-601 [16880743.001]
  • [Cites] Pediatr Blood Cancer. 2006 Oct 15;47(5):560-6 [16395684.001]
  • [Cites] Leuk Lymphoma. 2006 Aug;47(8):1545-52 [16966265.001]
  • [Cites] Mol Cancer Res. 2006 Sep;4(9):607-19 [16966431.001]
  • [Cites] Bone Marrow Transplant. 2006 Oct;38(7):493-9 [16980997.001]
  • [Cites] Hum Mol Genet. 2006 Oct 15;15 Spec No 2:R210-9 [16987886.001]
  • [Cites] Ann Oncol. 2006 Nov;17(11):1620-4 [16600978.001]
  • [Cites] Stem Cells. 2006 Nov;24(11):2319-45 [16794264.001]
  • [Cites] Klin Padiatr. 2006 Nov-Dec;218(6):321-6 [17080334.001]
  • [Cites] Int J Cancer. 2007 Jan 1;120(1):160-9 [17013895.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 7;103(45):16870-5 [17077147.001]
  • [Cites] Panminerva Med. 2006 Sep;48(3):165-74 [17122752.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:219-25 [17124064.001]
  • [Cites] J Cell Mol Med. 2006 Oct-Dec;10(4):857-65 [17125590.001]
  • [Cites] J Cell Mol Med. 2006 Oct-Dec;10(4):995-1013 [17125601.001]
  • [Cites] Clin Invest Med. 2006 Oct;29(5):301-11 [17144440.001]
  • [Cites] Exp Cell Res. 2006 Nov 15;312(19):3701-10 [17046749.001]
  • [Cites] Mol Vis. 2005;11:729-37 [16179903.001]
  • [Cites] Hematology. 2005 Oct;10(5):349-59 [16203604.001]
  • [Cites] Expert Rev Anticancer Ther. 2005 Oct;5(5):835-46 [16221053.001]
  • [Cites] Expert Rev Vaccines. 2005 Oct;4(5):699-710 [16221071.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):323-35 [16226707.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9328-37 [16230395.001]
  • [Cites] Chest. 2005 Oct;128(4):2268-73 [16236883.001]
  • [Cites] Pancreas. 2005 Nov;31(4):301-16 [16258363.001]
  • [Cites] Curr Opin Neurol. 2005 Dec;18(6):639-44 [16280674.001]
  • [Cites] Cancer Lett. 2005 Dec 18;230(2):199-210 [16297706.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2304-12 [16193083.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10946-51 [16322242.001]
  • [Cites] Haematologica. 2007 Mar;92(3):323-31 [17339181.001]
  • [Cites] PLoS One. 2007;2(3):e293 [17356702.001]
  • [Cites] Br J Haematol. 2007 Apr;137(1):20-35 [17359369.001]
  • [Cites] Mol Cancer Ther. 2007 Mar;6(3):967-78 [17363490.001]
  • [Cites] Semin Cancer Biol. 2007 Jun;17(3):241-7 [16839774.001]
  • [Cites] Bone Marrow Transplant. 2007 Apr;39(7):397-400 [17322933.001]
  • [Cites] Cancer Metastasis Rev. 2007 Mar;26(1):203-14 [17273942.001]
  • [Cites] J Thorac Oncol. 2007 Apr;2(4):327-43 [17409807.001]
  • [Cites] Adv Cancer Res. 2007;97:25-60 [17419940.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 2007 Mar;115(3):160-5 [17427103.001]
  • [Cites] Oncology. 2006;71(1-2):32-9 [17344669.001]
  • [Cites] Exp Gerontol. 2007 May;42(5):385-90 [17275237.001]
  • [Cites] Curr Eye Res. 2007 Mar;32(3):281-90 [17453948.001]
  • [Cites] Leukemia. 2007 May;21(5):926-35 [17330101.001]
  • [Cites] Nat Rev Drug Discov. 2006 Aug;5(8):649-59 [16883303.001]
  • [Cites] Leukemia. 2007 May;21(5):949-55 [17361218.001]
  • [Cites] Cancer Cell. 2007 May;11(5):421-9 [17482132.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Jun;62(3):214-26 [17368038.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2007 Jun 29;362(1482):959-71 [17317642.001]
  • [Cites] Trends Mol Med. 2007 May;13(5):192-9 [17383232.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Jun 15;357(4):1084-9 [17466949.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4807-15 [17510410.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4827-33 [17510412.001]
  • [Cites] J Cell Sci. 2007 Feb 1;120(Pt 3):468-77 [17227796.001]
  • [Cites] Nature. 2004 Oct 7;431(7009):707-12 [15361885.001]
  • [Cites] Nature. 1984 Feb 2-8;307(5950):471-3 [6694739.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):165-72 [9440739.001]
  • [Cites] Nat Med. 1998 Sep;4(9):1038-45 [9734397.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):324-31 [15549094.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Springer Semin Immunopathol. 2004 Nov;26(1-2):95-108 [15378271.001]
  • [Cites] Oncogene. 2004 Dec 16;23(58):9392-400 [15558011.001]
  • [Cites] J Clin Oncol. 2005 Jan 10;23(2):293-300 [15637392.001]
  • [Cites] Carcinogenesis. 2005 Feb;26(2):495-502 [15513931.001]
  • [Cites] Cell Cycle. 2004 Dec;3(12):1502-5 [15611623.001]
  • [Cites] Nat Rev Cancer. 2005 Feb;5(2):91-101 [15685194.001]
  • [Cites] J Neurooncol. 2005 Jan;71(1):33-8 [15719272.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):275-84 [15803154.001]
  • [Cites] Bone Marrow Transplant. 2005 Apr;35(8):763-6 [15750608.001]
  • [Cites] Med Hypotheses. 2005;64(6):1182-7 [15823713.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3025-9 [15833827.001]
  • [Cites] Am J Clin Oncol. 2005 Jun;28(3):281-8 [15923802.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4490-5 [15930263.001]
  • [Cites] Breast Cancer Res. 2005;7(3):86-95 [15987436.001]
  • [Cites] J Pediatr Surg. 2005 Jun;40(6):936-41; discussion 941 [15991174.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5506-11 [15994920.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6207-19 [16024622.001]
  • [Cites] Neoplasia. 2005 Jun;7(6):623-9 [16036113.001]
  • [Cites] Lancet. 2005 Jul 23-29;366(9482):318-20 [16039336.001]
  • [Cites] Br J Haematol. 2005 Aug;130(3):373-81 [16042686.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):119-30 [16098465.001]
  • [Cites] N Engl J Med. 2005 Aug 25;353(8):811-22 [16120861.001]
  • [Cites] Cancer Cell. 2008 Feb;13(2):153-66 [18242515.001]
  • [Cites] Cell Death Differ. 2008 Mar;15(3):504-14 [18049477.001]
  • [Cites] J Cell Physiol. 2008 May;215(2):287-91 [18205182.001]
  • [Cites] BMC Cancer. 2008;8:48 [18261235.001]
  • [Cites] Growth Factors. 2007 Dec;25(6):400-16 [18365871.001]
  • [Cites] Cell Stem Cell. 2007 Sep 13;1(3):313-23 [18371365.001]
  • [Cites] Endocr Rev. 2008 Apr;29(2):234-52 [18292464.001]
  • [Cites] Clin Pharmacol Ther. 2008 May;83(5):673-91 [17786164.001]
  • [Cites] Breast Cancer Res. 2008;10(1):R10 [18241344.001]
  • [Cites] Semin Oncol. 2005 Dec;32(6 Suppl 9):S78-81 [16399438.001]
  • [Cites] J Invest Dermatol. 2006 Jan;126(1):142-53 [16417230.001]
  • [Cites] J Exp Med. 2006 Jan 23;203(1):73-85 [16380511.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):1022-31 [16108016.001]
  • [Cites] Cancer. 2006 Feb 15;106(4):859-66 [16419074.001]
  • [Cites] Nat Rev Drug Discov. 2006 Feb;5(2):147-59 [16424916.001]
  • [Cites] Cell Cycle. 2006 Feb;5(4):452-6 [16479164.001]
  • [Cites] Oncogene. 2006 Mar 16;25(12):1696-708 [16449977.001]
  • [Cites] J Pediatr Surg. 2006 Apr;41(4):624-32; discussion 624-32 [16567167.001]
  • [Cites] Stem Cells. 2006 Mar;24(3):506-13 [16239320.001]
  • [Cites] J Clin Oncol. 2006 Apr 20;24(12):1924-31 [16567768.001]
  • [Cites] Hum Cell. 2006 Feb;19(1):24-9 [16643604.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4553-7 [16651403.001]
  • [Cites] Blood. 2006 Jun 1;107(11):4532-9 [16469872.001]
  • [Cites] Leuk Lymphoma. 2006 Jan;47(1):1-7 [16321820.001]
  • [Cites] Neoplasia. 2005 Nov;7(11):967-76 [16331882.001]
  • [Cites] Nature. 2005 Dec 8;438(7069):820-7 [16341007.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11459-68 [16357154.001]
  • [Cites] Carcinogenesis. 2006 Jan;27(1):1-22 [16195239.001]
  • [Cites] Nat Rev Neurosci. 2006 Jan;7(1):75-84 [16371952.001]
  • [Cites] Adv Cancer Res. 2007;96:23-50 [17161675.001]
  • [Cites] Mol Cancer. 2006;5:67 [17140455.001]
  • [Cites] Mod Pathol. 2007 Jan;20(1):102-7 [17143262.001]
  • [Cites] Semin Diagn Pathol. 2006 May;23(2):63-9 [17193819.001]
  • [Cites] PLoS Med. 2006 Dec;3(12):e482 [17194186.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] PLoS One. 2006;1:e23 [17183650.001]
  • [Cites] Pediatr Blood Cancer. 2007 Mar;48(3):349-53 [16302216.001]
  • [Cites] Annu Rev Med. 2007;58:267-84 [17002552.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):69-82 [17222791.001]
  • [Cites] Expert Opin Biol Ther. 2006 Dec;6(12):1255-62 [17223735.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):973-8 [17210912.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Curr Biol. 2007 Jan 23;17(2):165-72 [17196391.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Feb;13(2):235-44 [17241929.001]
  • [Cites] Neurosurg Clin N Am. 2007 Jan;18(1):59-69, viii-ix [17244554.001]
  • [Cites] Neurosurg Clin N Am. 2007 Jan;18(1):71-80, ix [17244555.001]
  • (PMID = 18427384.001).
  • [ISSN] 0031-0808
  • [Journal-full-title] Panminerva medica
  • [ISO-abbreviation] Panminerva Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA078590; United States / NCI NIH HHS / CA / U01 CA111294; United States / NCI NIH HHS / CA / CA111294; United States / NCI NIH HHS / CA / CA78590
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] Italy
  • [Number-of-references] 210
  • [Other-IDs] NLM/ NIHMS526856; NLM/ PMC3828640
  •  go-up   go-down


7. Alkatan HM, Maktabi A: Malignant fibrous histiocytoma in a patient with history of treated retinoblastoma. Saudi J Ophthalmol; 2010 Jan;24(1):23-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We are presenting a 22 year-old Saudi male with history of bilateral retinoblastoma, who was initially treated by enucleation of his left eye.
  • The histopathology showed a moderately differentiated tumor with vitreous seeding and he received chemotherapy in addition to radiotherapy to his right eye.
  • The excisional biopsy of his orbital mass revealed a spindle cell sarcoma with features of malignant fibrous histiocytoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23960869.001).
  • [ISSN] 1319-4534
  • [Journal-full-title] Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society
  • [ISO-abbreviation] Saudi J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  • [Other-IDs] NLM/ PMC3729799
  • [Keywords] NOTNLM ; Orbit / Retinoblastoma / Second tumors
  •  go-up   go-down


8. Poulaki V, Mitsiades CS, Mitsiades N: The role of Fas and FasL as mediators of anticancer chemotherapy. Drug Resist Updat; 2001 Aug;4(4):233-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of Fas and FasL as mediators of anticancer chemotherapy.
  • Several groups have suggested that it also participates in the mechanism of action of DNA-damaging anticancer drugs.
  • However, others have disputed this hypothesis, based largely on the inability of exogenously added anti-Fas/FasL reagents to attenuate drug-induced apoptosis in their studies.
  • In this minireview, we discuss the most recent evidence for and against the involvement of FasL/Fas in the sensitivity and resistance to chemotherapy in a variety of models.
  • In our own model of Ewing's sarcoma (ES), we have extensively investigated the involvement of the FasL/Fas pathway in doxorubicin (Dox)-induced apoptosis.
  • Therefore, commercially available Fas/FasL neutralizing reagents may not be a reliable indicator of the involvement of the Fas pathway in anticancer-drug-induced apoptosis and experiments using these agents should be carefully re-evaluated.
  • The combined use of MMP inhibitors with conventional, cytotoxic chemotherapy may hold therapeutic benefit.
  • [MeSH-major] Antigens, CD95 / physiology. Antineoplastic Agents / therapeutic use. Membrane Glycoproteins / physiology. Sarcoma, Ewing / drug therapy
  • [MeSH-minor] Animals. Apoptosis / drug effects. Apoptosis / physiology. Fas Ligand Protein. Humans

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Harcourt Publishers Ltd.
  • (PMID = 11991678.001).
  • [ISSN] 1368-7646
  • [Journal-full-title] Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  • [ISO-abbreviation] Drug Resist. Updat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Antineoplastic Agents; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Membrane Glycoproteins
  • [Number-of-references] 116
  •  go-up   go-down


9. Alexander C, Lee GA, Whitehead K, Bashford J, Jefferies PD: Life-threatening conjunctival presentation of myeloid sarcoma. Clin Exp Ophthalmol; 2008 Nov;36(8):775-7
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Life-threatening conjunctival presentation of myeloid sarcoma.
  • Myeloid sarcoma is a life-threatening condition that can present rarely as a conjunctival lesion.
  • This case report describes a 48-year-old woman who was diagnosed after conjunctival biopsy, subsequently systemically investigated and then treated with chemotherapy.
  • [MeSH-major] Conjunctival Neoplasms / pathology. Leukemia, Myeloid, Acute / pathology. Neoplasms, Second Primary. Sarcoma, Myeloid / pathology
  • [MeSH-minor] Antibiotics, Antineoplastic / therapeutic use. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Cytarabine / therapeutic use. Etoposide / therapeutic use. Female. Humans. Idarubicin / therapeutic use. Middle Aged. Skin Neoplasms / drug therapy. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Myeloid sarcoma.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19128384.001).
  • [ISSN] 1442-9071
  • [Journal-full-title] Clinical & experimental ophthalmology
  • [ISO-abbreviation] Clin. Experiment. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; ZRP63D75JW / Idarubicin
  •  go-up   go-down


10. Dutton JJ, Rose JG Jr, DeBacker CM, Gayre G: Orbital Ewing's sarcoma of the orbit. Ophthal Plast Reconstr Surg; 2000 Jul;16(4):292-300
Genetic Alliance. consumer health - Ewing's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital Ewing's sarcoma of the orbit.
  • This tumor may be confused with other small round cell malignancies of childhood, and immunohistochemical studies are essential in making the diagnosis.
  • The diagnosis is typically unsuspected before histologic evaluation.
  • Electron microscopic and immunohistochemical analyses are essential in making the diagnosis and are necessary for all such small round cell tumors.
  • CONCLUSIONS: Ewing's sarcoma is a rare orbital tumor of bone mainly affecting children.
  • Local treatment relying on surgical extirpation and radiotherapy alone has proven inadequate, with 5-year survival rates of <10%.
  • The addition of chemotherapy has improved survival rates significantly to approximately 50%.
  • [MeSH-major] Orbital Neoplasms / diagnosis. Sarcoma, Ewing / diagnosis
  • [MeSH-minor] Biopsy. Child. Child, Preschool. Diagnosis, Differential. Fatal Outcome. Humans. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10923978.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


11. Wilson DJ, Dailey RA, Griffeth MT, Newton CJ: Primary Ewing sarcoma of the orbit. Ophthal Plast Reconstr Surg; 2001 Jul;17(4):300-3
Genetic Alliance. consumer health - Ewing's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary Ewing sarcoma of the orbit.
  • PURPOSE: To report the clinicopathologic features of a 17-year-old patient with primary Ewing sarcoma of the orbit.
  • METHODS: The patient was evaluated clinically before surgery with computed tomography scans of the orbit.
  • After surgery, the patient was staged with computed tomography scans and bone scan and was treated with systemic chemotherapy and radiation therapy to the orbit.
  • Computed tomography scans disclosed a mass involving the superior orbit, anterior cranial fossa, and temporal fossa.
  • Computed tomography scan, bone scan, and blood chemistries revealed no other site of involvement.
  • After treatment, the clinical symptoms and signs resolved, and there has been no evidence of residual orbital tumor or metastasis.
  • CONCLUSIONS: Primary Ewing sarcoma of the orbit should be considered in the differential diagnosis of children or young adults with proptosis, diplopia, or periorbital swelling.
  • Immunohistochemistry is essential to distinguish Ewing sarcoma from other small round cell tumors.
  • [MeSH-major] Orbital Neoplasms / pathology. Sarcoma, Ewing / pathology
  • [MeSH-minor] Adolescent. Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11476182.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


12. Yip CC, Kersten RC, McCulley TJ, Ballard ET, Kulwin DR: Osteogenic sarcoma after orbital radiation rhabdomyosarcoma. Ophthalmology; 2003 Oct;110(10):1996-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteogenic sarcoma after orbital radiation rhabdomyosarcoma.
  • PURPOSE: We describe the occurrence of maxillary and orbital osteogenic sarcoma in a child after treatment of contralateral orbital rhabdomyosarcoma with external beam radiation and chemotherapy.
  • INTERVENTION: Treatment of a maxillary and orbital rhabdomyosarcoma with surgical resection, systemic chemotherapy, and local radiation.
  • RESULTS: An eleven year-old male presented for evaluation of left facial swelling, occurring ten years after successful treatment of a right orbital embryonal rhabdomyosarcoma with chemotherapy and 5040 cGY of external beam radiation.
  • Computerized tomography demonstrated a mass involving the left maxillary sinus and orbital floor.
  • Biopsy demonstrated osteogenic sarcoma.
  • Postoperatively he was treated with systemic chemotherapy and local radiation.
  • CONCLUSIONS: Osteogenic sarcoma can occur as a secondary malignancy years after the successful treatment of orbital rhabdomyosarcoma with external beam radiation and chemotherapy.
  • [MeSH-minor] Child. Combined Modality Therapy. Humans. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14522778.001).
  • [ISSN] 0161-6420
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


13. Lakhkar BN, Banavali S, Philip P: Orbital granulocytic sarcoma in acute myelogenous leukemia. Indian J Pediatr; 2000 Mar;67(3):234-5
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital granulocytic sarcoma in acute myelogenous leukemia.
  • A five year old boy presented with progressively increasing proptosis of the left eye.
  • CT scan showed bilateral extra-conal homogeneously enhancing soft tissue masses, larger on the left side.
  • A possibility of granulocytic sarcoma of the orbit was considered.
  • Diagnosis was confirmed by peripheral smear and bone marrow aspiration.
  • Patient responded to chemotherapy.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis. Orbital Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1978 Apr;41(4):1606-9 [205341.001]
  • [Cites] Radiology. 1994 Mar;190(3):698-702 [8115614.001]
  • [Cites] Cancer. 1973 Apr;31(4):948-55 [4513297.001]
  • [Cites] Radiology. 1985 Apr;155(1):167-70 [3856292.001]
  • [Cites] Ophthalmologica. 1998;212(3):202-5 [9562099.001]
  • [Cites] Br Med J. 1965 Aug 14;2(5458):405-7 [20722188.001]
  • [Cites] Ophthalmology. 1985 Dec;92(12):1758-62 [3867055.001]
  • [Cites] Am J Ophthalmol. 1975 Dec;80(6):975-90 [1060381.001]
  • (PMID = 10838728.001).
  • [ISSN] 0019-5456
  • [Journal-full-title] Indian journal of pediatrics
  • [ISO-abbreviation] Indian J Pediatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


14. Pang NK, Bartley GB, Giannini C: Primary Ewing sarcoma of the orbit in an adult. Ophthal Plast Reconstr Surg; 2007 Mar-Apr;23(2):153-4
Genetic Alliance. consumer health - Ewing's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary Ewing sarcoma of the orbit in an adult.
  • A 42-year-old man presented with visual field loss in the right eye and unintentional weight loss associated with a right orbital mass.
  • Surgical resection and biopsy revealed a diagnosis of Ewing sarcoma, and systemic evaluation showed no metastasis.
  • Subsequent chemotherapy and radiation resulted in tumor resolution without recurrence for 3.5 years.
  • [MeSH-major] Orbital Neoplasms / pathology. Sarcoma, Ewing / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Magnetic Resonance Imaging. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17413636.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


15. Thomas SA, Durairaj VD: Isolated myeloid sarcoma presenting in all four eyelids. Ophthal Plast Reconstr Surg; 2007 Jul-Aug;23(4):336-8
Genetic Alliance. consumer health - Myeloid sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated myeloid sarcoma presenting in all four eyelids.
  • Myeloid sarcoma is an unusual manifestation of acute leukemia.
  • Leukemia is almost always present, but may be undiagnosed when the myeloid sarcoma comes to medical attention.
  • We present a clinicopathologic report of a previously healthy young woman with conjunctival myeloid sarcomas of all 4 eyelids without evidence of an underlying hematologic disorder over 15 months' follow-up, despite refusal of consolidation chemotherapy.
  • Isolated, multifocal myeloid sarcoma of the periorbital region is a very rare manifestation of acute leukemia.
  • [MeSH-major] Conjunctival Neoplasms / pathology. Eyelid Neoplasms / pathology. Leukemia, Monocytic, Acute / pathology. Sarcoma, Myeloid / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Combined Modality Therapy. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17667120.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


16. Buono LM, Silberschmidt A, Foroozan R, Savino PJ: Metastatic synovial sarcoma to the skull base and orbit. Am J Ophthalmol; 2002 Nov;134(5):785-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic synovial sarcoma to the skull base and orbit.
  • PURPOSE: To report a case of metastatic synovial sarcoma to the parasellar area and orbit.
  • METHODS: A 43-year-old woman with a history of a right forearm synovial sarcoma treated with excision, radiation, and chemotherapy 16 months previously presented with blurred vision of the right eye, pain with eye movement, epistaxis, and a right superior division cranial nerve III palsy.
  • RESULTS: Pathologic examination of the parasellar biopsy revealed metastatic synovial sarcoma.
  • CONCLUSIONS: Metastatic synovial sarcoma should be added to the differential diagnosis of parasellar and orbital tumors.
  • [MeSH-major] Orbital Neoplasms / secondary. Sarcoma, Synovial / secondary. Skull Base Neoplasms / secondary. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Forearm. Humans. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12429268.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Apostolopoulos K, Ferekidis E: Extensive primary Ewings' sarcoma in the greater wing of the sphenoid bone. ORL J Otorhinolaryngol Relat Spec; 2003 Jul-Aug;65(4):235-7
Genetic Alliance. consumer health - Ewing's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extensive primary Ewings' sarcoma in the greater wing of the sphenoid bone.
  • We describe a rare case of an extensive primary cranial Ewing's sarcoma located in the greater wing of the sphenoid bone with extension to the orbit, the endocranium, the parapharyngeal and infratemporal space.
  • The patient presented with diplopia, anosmia and prolapse of the left eye.
  • The prognosis of Ewing's sarcoma in the absence of surgery is uncertain, but prompt treatment appears to have a satisfactory therapeutic outcome.
  • In the future, more cases should be studied in order to investigate the biological behaviour of a primary cranial Ewing's sarcoma.
  • [MeSH-major] Sarcoma, Ewing / diagnosis. Sarcoma, Ewing / drug therapy. Skull Neoplasms / diagnosis. Skull Neoplasms / drug therapy. Sphenoid Bone / pathology
  • [MeSH-minor] Adult. Cranial Fossa, Middle / pathology. Humans. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Orbit / pathology. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger AG, Basel
  • (PMID = 14564101.001).
  • [ISSN] 0301-1569
  • [Journal-full-title] ORL; journal for oto-rhino-laryngology and its related specialties
  • [ISO-abbreviation] ORL J. Otorhinolaryngol. Relat. Spec.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


18. Qureshi YA, Karp CL, Dubovy SR: Intralesional interferon alpha-2b therapy for adnexal Kaposi sarcoma. Cornea; 2009 Sep;28(8):941-3
MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intralesional interferon alpha-2b therapy for adnexal Kaposi sarcoma.
  • PURPOSE: To describe a case of adnexal Kaposi's sarcoma successfully treated with intralesional interferon alpha 2b injections.
  • Clinical, histological, and immunohistochemical examination yielded the diagnosis of Kaposi's sarcoma.
  • The patient was subsequently diagnosed with AIDS, started on highly active anti-retroviral therapy (HAART) and systemic doxorubicin, and initially received topical 3 million IU per mL of interferon alpha-2b eyedrops (Intron-A(R), Schering Corporation, Kenilworth, NJ) every 6 hours to the right eye for 9 weeks.
  • This systemic therapy resulted in minimal clinical response with a CD4 count increase from 12 to 61 cells per microliter.
  • CONCLUSION: Ocular adnexal and conjunctival Kaposi's sarcoma was successfully treated with 3 adjuvant intralesional interferon alpha-2b injections leading to a dramatic decrease in tumor mass.
  • [MeSH-major] Antiviral Agents / administration & dosage. Conjunctival Neoplasms / drug therapy. Eyelid Neoplasms / drug therapy. Interferon-alpha / administration & dosage. Neoplasms, Adnexal and Skin Appendage / drug therapy. Sarcoma, Kaposi / drug therapy
  • [MeSH-minor] Adult. Disease Progression. Edema / etiology. Entropion / etiology. Entropion / pathology. Eyelashes. Eyelid Diseases / etiology. Hair Diseases / etiology. Humans. Injections, Intralesional. Male. Recombinant Proteins. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19654515.001).
  • [ISSN] 1536-4798
  • [Journal-full-title] Cornea
  • [ISO-abbreviation] Cornea
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


19. Pinarli FG, Oğuz A, Karadeniz C, Uluoğlu O, Akyürek N: Second primary myogenic sarcoma in a patient with bilateral retinoblastoma. Pediatr Hematol Oncol; 2004 Sep;21(6):545-50
MedlinePlus Health Information. consumer health - Eye Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second primary myogenic sarcoma in a patient with bilateral retinoblastoma.
  • The authors report a patient with bilateral retinoblastoma who developed a myogenic sarcoma of the orbit after 5.5 years of diagnosis.
  • The short latency period may be explained by tumor histology with the contribution of radiotherapy and chemotherapy.
  • The prognosis of second tumors is poor despite aggressive treatment.
  • [MeSH-major] Eye Neoplasms / pathology. Neoplasms, Second Primary / pathology. Retinoblastoma / pathology. Rhabdomyosarcoma / pathology

  • Genetic Alliance. consumer health - Retinoblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15552818.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


20. Brasnu E, Wechsler B, Bron A, Charlotte F, Bliefeld P, Lehoang P, Marcelin AG, Bodaghi B: Efficacy of interferon-alpha for the treatment of Kaposi's sarcoma herpesvirus-associated uveitis. Am J Ophthalmol; 2005 Oct;140(4):746-8
MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of interferon-alpha for the treatment of Kaposi's sarcoma herpesvirus-associated uveitis.
  • PURPOSE: To report cases of uveitis that are associated with human herpesvirus-8 (HHV-8) and the impact of interferon-alpha therapy on their visual outcome.
  • METHODS: Extensive examination was performed in patients with chronic and severe uveitis to exclude a viral cause that requires specific therapy.
  • After histopathologic, molecular, and/or serologic confirmation of HHV-8 uveitis, interferon-alpha2a therapy (3 millions IU/d, 3 days per week, subcutaneously) was initiated.
  • Histopathologic examination of conjunctival biopsy specimens confirmed Kaposi's sarcoma in the second case, and quantitative polymerase chain reaction identified HHV-8 DNA in the biopsy specimen.
  • Disease was controlled by interferon-alpha2a in both cases, but maintenance therapy was mandatory to prevent relapses.
  • Severe and chronic conditions may require antiviral and immunomodulatory therapies.
  • [MeSH-major] Eye Infections, Viral / drug therapy. Herpesvirus 8, Human / isolation & purification. Interferon-alpha / therapeutic use. Sarcoma, Kaposi / drug therapy. Uveitis / drug therapy
  • [MeSH-minor] Aged. Antiviral Agents / therapeutic use. Biopsy. Child. Conjunctivitis / pathology. Conjunctivitis / virology. DNA, Viral / analysis. Female. Humans. Polymerase Chain Reaction. Recombinant Proteins

  • Genetic Alliance. consumer health - Uveitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16226536.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / DNA, Viral; 0 / Interferon-alpha; 0 / Recombinant Proteins; 76543-88-9 / interferon alfa-2a
  •  go-up   go-down


21. Scheinfeld N: A review of deferasirox, bortezomib, dasatinib, and cyclosporine eye drops: possible uses and known side effects in cutaneous medicine. J Drugs Dermatol; 2007 Mar;6(3):352-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A review of deferasirox, bortezomib, dasatinib, and cyclosporine eye drops: possible uses and known side effects in cutaneous medicine.
  • Recently, a number of medications approved for nondermatologic use have proved useful against dermatologic diseases.
  • This article reviews the dermatologic uses and effects of deferasirox, bortezomib, dasatinib, and cyclosporine eye drops.
  • Deferasirox--an oral iron chelator--could be an effective treatment against porphyria cutanea tarda, hemochromatosis, and pathogens such as mucor that thrive in iron rich environments.
  • Bortezomib, a proteasome inhibitor and multiple myeloma treatment, may be effective against nodular amyloid and has been effectively used against squamous cell carcinoma; although trials demonstrate it is ineffective against metastatic melanoma.
  • Dasatinib is likely to be effective against dermatofibroma sarcoma protuberans and cutaneous acute lymphoblastic leukemia, and has caused panniculitis.
  • Cyclosporine 0.05% ocular emulsion (eye drops) are approved to treat dry eyes including dry eyes caused by collagen vascular disease.
  • Cyclosporine eye drops might also have utility in treating eye pathology of ocular rosacea, atopic keratoconjunctivitis, graft versus host disease, herpes keratitis, chronic sarcoidosis of the conjunctiva, conjunctival manifestations of actinic prurigo, keratitis of keratitis-ichthyosis deafness (KID) syndrome, and lichen planus-related kerato-conjunctivitis.
  • This article speculates that cyclosporine eye drops would also be useful for any disease causing ectropion or eclabion of the eye as well as toxic epidermal necrolysis-related eye pathology (in particular corneal scarring).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzoates / therapeutic use. Boronic Acids / therapeutic use. Cyclosporine / therapeutic use. Iron Chelating Agents / therapeutic use. Protein Kinase Inhibitors / therapeutic use. Pyrazines / therapeutic use. Pyrimidines / therapeutic use. Skin Diseases / drug therapy. Skin Neoplasms / drug therapy. Thiazoles / therapeutic use. Triazoles / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17373201.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzoates; 0 / Boronic Acids; 0 / Iron Chelating Agents; 0 / Ophthalmic Solutions; 0 / Protein Kinase Inhibitors; 0 / Pyrazines; 0 / Pyrimidines; 0 / Thiazoles; 0 / Triazoles; 69G8BD63PP / Bortezomib; 83HN0GTJ6D / Cyclosporine; RBZ1571X5H / Dasatinib; V8G4MOF2V9 / deferasirox
  • [Number-of-references] 36
  •  go-up   go-down


22. Frikha H, Chaari N, Nasr C, Bouguila H, Chebbi A, Bhouri L, Hentati D, Kochbati L, Besbes M, Rifi H, Oubiche F, Ayed S, Maalej M: [Radiotherapy in the treatment of retinoblastoma: about 40 cases]. Cancer Radiother; 2009 Jan;13(1):30-6
Genetic Alliance. consumer health - Retinoblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Radiotherapy in the treatment of retinoblastoma: about 40 cases].
  • [Transliterated title] Place de la radiothérapie dans le traitement du rétinoblastome : à propos de 40 cas.
  • PURPOSE: The aim of this study is to analyze the results and the complications of radiotherapy in the treatment of retinoblastoma.
  • The average dose was 44 Gy (1.8 to 2 Gy per fraction, five fractions weekly).
  • This radiotherapy was associated with chemotherapy in 24 cases.
  • The conservation of the eye with a useful visual field was noted in 18 cases among the 20 conservative irradiated eyes.
  • The major therapeutic complication was the growth defect of the bones face.
  • A femoral bone sarcoma was noted five years after the end of the irradiation and chemotherapy in one case.
  • CONCLUSION: If the radiotherapy offers the advantage of the functional conservation and the improvement of the local control, its indications are more and more restricted in favor of the other therapeutic methods (chemotherapy, thermochemotherapy) and this considering the iatrogene risk.
  • [MeSH-minor] Brachytherapy. Cataract / epidemiology. Cataract / etiology. Chemotherapy, Adjuvant. Child. Child, Preschool. Consanguinity. Cranial Irradiation. Eye Enucleation. Female. Humans. Infant. Male. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Patient Selection. Radiotherapy / adverse effects. Radiotherapy / methods. Radiotherapy Dosage. Radiotherapy, Adjuvant. Radiotherapy, Conformal. Restraint, Physical / methods. Retrospective Studies. Treatment Outcome. Tunisia / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18790660.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


23. Kiratli H, Demiroğlu H, Emeç S: Ocular relapse in acute myeloid leukemia (M4) with normal bone marrow. Int Ophthalmol; 2009 Aug;29(4):243-5
MedlinePlus Health Information. consumer health - Eye Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 47-year-old woman with AML was treated with chemotherapy and went successfully into remission.
  • Four months later, she presented with pain, redness, and a mass over the left eye.
  • The ocular relapse involved the subconjunctival space and anterior chamber of the left eye and, presumably, the left lacrimal gland.
  • Although exceedingly rare, ocular extramedullary relapse in AML M4 heralds bone marrow recurrence and, despite intensive chemotherapy, the prognosis is dismal.
  • [MeSH-major] Bone Marrow / pathology. Eye / pathology. Leukemia, Myeloid, Acute / complications. Leukemia, Myeloid, Acute / pathology. Sarcoma, Myeloid / etiology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Fatal Outcome. Female. Humans. Leukapheresis. Leukemic Infiltration / etiology. Middle Aged. Recurrence. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1999 Feb 1;85(3):608-15 [10091734.001]
  • [Cites] N Z Med J. 1996 Jun 28;109(1024):242 [8769042.001]
  • [Cites] Hematol Oncol. 1999 Jun;17(2):45-52 [10521868.001]
  • [Cites] Bone Marrow Transplant. 1996 May;17(5):801-8 [8733701.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1800-16 [7602369.001]
  • [Cites] Am J Ophthalmol. 1999 Mar;127(3):361-3 [10088758.001]
  • (PMID = 18338107.001).
  • [ISSN] 1573-2630
  • [Journal-full-title] International ophthalmology
  • [ISO-abbreviation] Int Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


24. Garrido Colino C, Mateos González M, Torres Valdivieso M, López Pérez J, Melero Moreno C, Vivanco Martínez J: [Ocular infiltration in the anterior chamber in a female infant with acute non-lymphoblastic leukemia]. An Esp Pediatr; 2001 Jul;55(1):69-72
MedlinePlus Health Information. consumer health - Eye Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Unlike myeloid sarcoma, ocular involvement is unusual in acute non-lymphoblastic leukemia.A 9-month-old female infant with acute non-lymphoblastic leukemia M5 and evidence of active central nervous system (CNS) disease showed infiltration of the anterior chamber during therapy.
  • At that time, the CNS disease was in completed remission.
  • She was treated with topical corticosteroids, chemotherapy and bilateral ocular radiotherapy (total dose 1,000 cGy).
  • The ocular manifestations responded well to treatment but hematologic response was poor.
  • Radiotherapy is warranted in infiltration of the anterior chamber of the eye.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Eye Neoplasms / diagnosis. Leukemia, Myeloid, Acute / diagnosis


25. Font RL, Ray R, Mazow ML, Del Valle M: Mesenchymal chondrosarcoma of the orbit: a unique radiologic-pathologic correlation. Ophthal Plast Reconstr Surg; 2009 May-Jun;25(3):219-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histopathologic examination of the orbital mass showed a biphasic pattern of a mesenchymal chondrosarcoma exhibiting features of a high-grade sarcoma with hemangiopericytoma pattern that corresponds to the radiopaque portion of the mass and areas of chondrosarcoma that correlated with the radiolucent component of the tumor.
  • The patient underwent exenteration of the left orbit followed by radiotherapy and chemotherapy.
  • The authors believe that recognizing the different radiologic features of the orbital tumor can help clinicians in establishing the correct preoperative diagnosis of this potentially lethal neoplasm.
  • [MeSH-major] Chondrosarcoma, Mesenchymal / pathology. Chondrosarcoma, Mesenchymal / radiography. Orbital Neoplasms / pathology. Orbital Neoplasms / radiography. Tomography, X-Ray Computed
  • [MeSH-minor] Asian Continental Ancestry Group. Chemotherapy, Adjuvant. Exophthalmos / etiology. Exophthalmos / radiography. Female. Follow-Up Studies. Humans. Orbit Evisceration. Radiotherapy, Adjuvant. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19454935.001).
  • [ISSN] 1537-2677
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


26. Grover A, Alexander HR Jr: The past decade of experience with isolated hepatic perfusion. Oncologist; 2004;9(6):653-64
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Regional treatment strategies including infusional chemotherapy and local ablative therapy are under investigation, but have limitations with respect to the clinical conditions under which they can be employed.
  • In light of the antitumor activity with isolated limb perfusion with tumor necrosis factor (TNF) and melphalan in patients with unresectable extremity sarcoma or in transit melanoma, this regimen has been administered via IHP at several centers worldwide for patients with unresectable liver cancers.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Chemotherapy, Cancer, Regional Perfusion / methods. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Melphalan / therapeutic use. Tumor Necrosis Factor-alpha / therapeutic use
  • [MeSH-minor] Colorectal Neoplasms / pathology. Eye Neoplasms / pathology. Humans. Hyperthermia, Induced. Melanoma / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15561809.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Tumor Necrosis Factor-alpha; Q41OR9510P / Melphalan
  • [Number-of-references] 68
  •  go-up   go-down


27. Doz F: [Retinoblatoma: a review]. Arch Pediatr; 2006 Oct;13(10):1329-37
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Retinoblastoma is the most frequent eye tumor in children, with an incidence of 1/15 000 births.
  • Sixty per cent are unilateral: the median age at diagnosis is 2 years and most of these forms are not hereditary.
  • Retinoblastoma is bilateral in 40%: the median age at diagnosis is 1 year.
  • Diagnosis is made by fundoscopy.
  • US, MRI, CT scans may contribute to diagnosis.
  • Enucleation is still often necessary in unilateral disease; adjuvant treatment is decided according to the histological risk factors.
  • Conservative treatment of at least 1 eye is possible in most of the bilateral cases: laser alone or combined with chemotherapy, cryotherapy and brachytherapy.
  • The indication for external beam radiotherapy should be restricted to large ocular tumors and diffuse vitreous seeding because of the risk of late effects, including secondary sarcoma.
  • [MeSH-major] Retinal Neoplasms / diagnosis. Retinal Neoplasms / therapy. Retinoblastoma / diagnosis. Retinoblastoma / therapy
  • [MeSH-minor] Child. Eye Enucleation. Genetic Predisposition to Disease. Humans. Ophthalmoscopy

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16930963.001).
  • [ISSN] 0929-693X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 38
  •  go-up   go-down


28. Mahesh L, Krishnakumar S, Subramanian N, Babu K, Biswas J: Malignant teratoma of the orbit: a clinicopathological study of a case. Orbit; 2003 Dec;22(4):305-9
Genetic Alliance. consumer health - Teratoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: A 10-month-old child presented with protrusion of the left eye of 8 months duration.
  • Computerized tomography (CT) revealed a heterogeneous retrobulbar mass in the left orbit.
  • The child was treated with chemotherapy and radiotherapy with a provisional diagnosis of sarcoma.
  • CONCLUSION: Orbital teratomas should be considered in the differential diagnosis of all neonatal orbital masses.
  • FNAB is not helpful in the diagnosis.
  • Surgical excision of the mass is recommended for a definitive diagnosis.
  • [MeSH-minor] Combined Modality Therapy. Humans. Infant. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14685907.001).
  • [ISSN] 0167-6830
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


29. Wang Y, Radfar S, Liu S, Riker AI, Khong HT: Mitf-Mdel, a novel melanocyte/melanoma-specific isoform of microphthalmia-associated transcription factor-M, as a candidate biomarker for melanoma. BMC Med; 2010;8:14
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment options, including chemotherapy and immunotherapy, are limited and offer low response rates and transient efficacy.
  • Expression was investigated using regular and quantitative RT-PCR in three normal melanocytes (NHEM), 31 melanoma cell lines, 21 frozen melanoma tissue samples, 18 blood samples (peripheral blood mononuclear cell;.
  • PBMC) from healthy donors and 12 non-melanoma cancer cell lines, including three breast, five glioma, one sarcoma, two kidney and one ovarian cancer cell lines.
  • MITF-Mdel was widely expressed in melanocytes, melanoma cell lines and tissues, but almost undetectable in non-melanoma cell lines or PBMC from healthy donors.
  • Both isoforms were expressed significantly higher in melanoma tissues than in cell lines.

  • Genetic Alliance. consumer health - Microphthalmia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Med Genet. 2000 Jun;37(6):446-8 [10851256.001]
  • [Cites] Biochim Biophys Acta. 2000 Apr 25;1491(1-3):205-19 [10760582.001]
  • [Cites] Pigment Cell Res. 2000 Aug;13(4):230-40 [10952390.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5012-6 [11016620.001]
  • [Cites] Arch Dermatol. 2001 Mar;137(3):325-30 [11255333.001]
  • [Cites] J Investig Dermatol Symp Proc. 2001 Nov;6(1):99-104 [11764295.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Feb 1;290(4):1250-4 [11811997.001]
  • [Cites] Biochim Biophys Acta. 2002 Feb 20;1574(1):15-23 [11955610.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3020-3 [12036907.001]
  • [Cites] Melanoma Res. 2002 Dec;12(6):585-92 [12459648.001]
  • [Cites] Exp Eye Res. 2004 Apr;78(4):837-48 [15037118.001]
  • [Cites] Cell. 1993 Jul 30;74(2):395-404 [8343963.001]
  • [Cites] Nat Genet. 1994 Aug;7(4):509-12 [7951321.001]
  • [Cites] Nat Genet. 1994 Nov;8(3):256-63 [7874168.001]
  • [Cites] Clin Dysmorphol. 1998 Jan;7(1):17-20 [9546825.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Jun 29;247(3):710-5 [9647758.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):731-8 [10487831.001]
  • [Cites] Prague Med Rep. 2004;105(3):318-24 [15782558.001]
  • [Cites] Gene. 2005 Feb 28;347(1):73-82 [15715979.001]
  • [Cites] Nature. 2005 Jul 7;436(7047):117-22 [16001072.001]
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1137-43 [16489066.001]
  • [Cites] Exp Hematol. 2006 Apr;34(4):528-35 [16569599.001]
  • [Cites] Genetics. 2008 Jan;178(1):259-72 [18202372.001]
  • [Cites] Genetics. 2009 Oct;183(2):581-94 [19635938.001]
  • [Cites] J Investig Dermatol Symp Proc. 1999 Sep;4(2):101-4 [10536982.001]
  • [Cites] J Biochem. 1999 Dec;126(6):1043-51 [10578055.001]
  • [Cites] Genes Dev. 2000 Jul 15;14(14):1712-28 [10898786.001]
  • (PMID = 20163701.001).
  • [ISSN] 1741-7015
  • [Journal-full-title] BMC medicine
  • [ISO-abbreviation] BMC Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Microphthalmia-Associated Transcription Factor; 0 / Protein Isoforms
  • [Other-IDs] NLM/ PMC2839965
  •  go-up   go-down


30. Shields JA, Shields CL, Brotman HK, Carvalho C, Perez N, Eagle RC Jr: Cancer metastatic to the orbit: the 2000 Robert M. Curts Lecture. Ophthal Plast Reconstr Surg; 2001 Sep;17(5):346-54
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of patients in whom a detailed history was available, there was no history of cancer at the time of presentation in 19%.
  • There were 36 male patients and 64 female patients whose mean age at diagnosis was 62 years (median 60 years, range 5 to 91 years).
  • Treatment included chemotherapy, hormone therapy, irradiation, surgical excision, or observation, depending on clinical circumstances.
  • Among patients with sufficient follow-up, 95% died of metastasis, with overall mean survival of 15 months (median 15 months; range 3 to 96 months) after orbital diagnosis.
  • [MeSH-major] Carcinoma / secondary. Melanoma / secondary. Neoplasms / pathology. Neuroblastoma / secondary. Orbital Neoplasms / secondary. Sarcoma / secondary
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Tomography, X-Ray Computed


31. Verhoef C, de Wilt JH, Brunstein F, Marinelli AW, van Etten B, Vermaas M, Guetens G, de Boeck G, de Bruijn EA, Eggermont AM: Isolated hypoxic hepatic perfusion with retrograde outflow in patients with irresectable liver metastases; a new simplified technique in isolated hepatic perfusion. Ann Surg Oncol; 2008 May;15(5):1367-74
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Isolated hepatic perfusion with high-dose chemotherapy is a treatment option for patients with irresectable metastases confined to the liver.
  • Major drawbacks are magnitude and costs of the procedure.
  • We developed an isolated hypoxic hepatic perfusion (IHHP) with retrograde outflow without the need for a heart-lung machine.
  • RESULTS: Compared with oxygenated classical IHP, the IHPP procedure reduced operation time from >8 h to 4 hours, blood loss from >4000 to 900 cc and saved material and personnel costs.
  • Median time to progression was 9 months (2-24 months); pharmacokinetics demonstrated intrahepatic melphalan concentrations more than 9 fold higher than postperfusion systemic concentrations.
  • CONCLUSIONS: IHPP is a relatively simple procedure with reduced costs, reduced blood loss, no mortality, limited toxicity, and response rates comparable to classic IHP.
  • Hereto, vasoactive drugs, will be explored in further studies.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Chemotherapy, Cancer, Regional Perfusion / methods. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Melphalan / therapeutic use
  • [MeSH-minor] Adult. Aged. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery. Disease Progression. Eye Neoplasms / drug therapy. Eye Neoplasms / pathology. Eye Neoplasms / surgery. Female. Follow-Up Studies. Gas Chromatography-Mass Spectrometry. Hepatic Artery / drug effects. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Neoplasms, Unknown Primary / drug therapy. Neoplasms, Unknown Primary / pathology. Neoplasms, Unknown Primary / surgery. Portal Vein / drug effects. Sarcoma / drug therapy. Sarcoma / pathology. Sarcoma / surgery. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pharmacol Exp Ther. 2002 Nov;303(2):736-40 [12388659.001]
  • [Cites] Semin Oncol. 2002 Apr;29(2):107-18 [11951208.001]
  • [Cites] Br J Surg. 2003 Nov;90(11):1391-7 [14598420.001]
  • [Cites] Clin Cancer Res. 2003 Dec 15;9(17):6343-9 [14695133.001]
  • [Cites] Ann Surg Oncol. 2004 Mar;11(3):290-7 [14993024.001]
  • [Cites] Melanoma Res. 2004 Feb;14(1):67-72 [15091197.001]
  • [Cites] Surg Clin North Am. 2004 Apr;84(2):627-41 [15062665.001]
  • [Cites] Ann Surg Oncol. 2004 Jun;11(6):598-605 [15172933.001]
  • [Cites] Eur J Cancer. 2004 Aug;40(12):1812-24 [15288282.001]
  • [Cites] Cancer Res. 1981 Jan;41(1):73-81 [7448778.001]
  • [Cites] Cancer. 1983 Jul 15;52(2):334-6 [6190546.001]
  • [Cites] Ann Surg. 1984 May;199(5):502-8 [6721600.001]
  • [Cites] Surg Gynecol Obstet. 1985 May;160(5):477-89 [3158090.001]
  • [Cites] Arch Surg. 1987 Nov;122(11):1273-7 [2960296.001]
  • [Cites] Cancer Res. 1989 Dec 1;49(23):6449-65 [2684393.001]
  • [Cites] J Chromatogr. 1990 Oct 12;531:235-94 [2258419.001]
  • [Cites] Ophthalmology. 1991 Mar;98(3):383-9; discussion 390 [2023760.001]
  • [Cites] Surv Ophthalmol. 1992 May-Jun;36(6):429-38 [1589858.001]
  • [Cites] Cancer. 1993 Oct 1;72(7):2219-23 [7848381.001]
  • [Cites] Acta Ophthalmol Scand. 1995 Aug;73(4):340-4 [8646581.001]
  • [Cites] Jpn J Clin Oncol. 1996 Oct;26(5):341-50 [8895675.001]
  • [Cites] Recent Results Cancer Res. 1998;147:107-19 [9670273.001]
  • [Cites] Ann Surg. 1998 Dec;228(6):763-70 [9860475.001]
  • [Cites] Oncologist. 2004;9(6):653-64 [15561809.001]
  • [Cites] Ann Surg Oncol. 2005 Feb;12(2):138-44 [15827794.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4300-8 [15899822.001]
  • [Cites] Cancer Invest. 2005;23(8):712-26 [16377590.001]
  • [Cites] Curr Pharm Des. 2006;12(21):2623-30 [16842162.001]
  • [Cites] Lancet. 2006 Dec 9;368(9552):2039-41 [17161715.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):795-801 [17096052.001]
  • [Cites] Br J Cancer. 2000 May;82(9):1539-46 [10789721.001]
  • [Cites] Oncologist. 2000;5(5):416-24 [11040278.001]
  • [Cites] Surgery. 2001 Feb;129(2):176-87 [11174711.001]
  • [Cites] Ann Oncol. 2001 Jul;12(7):887-94 [11521792.001]
  • [Cites] Lancet Oncol. 2001 Jul;2(7):418-28 [11905736.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Jun;305(3):1098-103 [12606622.001]
  • (PMID = 18239976.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; Q41OR9510P / Melphalan
  • [Other-IDs] NLM/ PMC2277449
  •  go-up   go-down


32. Jeng BH, Holland GN, Lowder CY, Deegan WF 3rd, Raizman MB, Meisler DM: Anterior segment and external ocular disorders associated with human immunodeficiency virus disease. Surv Ophthalmol; 2007 Jul-Aug;52(4):329-68
HIV InSite. treatment guidelines - Ophthalmic Manifestations of HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The eye is a common site for complications of human immunodeficiency virus (HIV) infection.
  • Some of these entities, such as Kaposi sarcoma, were well described, but uncommon, before the HIV epidemic.
  • The treatment of many of these diseases is challenging because of host immunodeficiency.
  • Survival after the diagnosis of AIDS has increased among individuals with HIV disease because of more effective antiretroviral therapies and improved prophylaxis against, and treatment of, opportunistic infections.
  • In addition, the evaluation and management of disorders such as blepharitis and dry eye, which were previously overshadowed by more severe, blinding disorders, may demand increased attention, as the general health of this population improves.
  • Not all individuals infected with HIV receive potent antiretroviral therapy, however, because of socioeconomic or other factors, and others will be intolerant of these drugs or experience drug failure.
  • [MeSH-major] Anterior Eye Segment / pathology. Eye Diseases / etiology. HIV Infections / complications
  • [MeSH-minor] Anti-Retroviral Agents / therapeutic use. Conjunctiva / pathology. Cornea / pathology. Eyelids / pathology. Humans. Prevalence. Prognosis

  • MedlinePlus Health Information. consumer health - Eye Diseases.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17574062.001).
  • [ISSN] 0039-6257
  • [Journal-full-title] Survey of ophthalmology
  • [ISO-abbreviation] Surv Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  • [Number-of-references] 592
  •  go-up   go-down


33. Aerts I, Lumbroso-Le Rouic L, Gauthier-Villars M, Brisse H, Doz F, Desjardins L: Retinoblastoma. Orphanet J Rare Dis; 2006;1:31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Retinoblastoma is a rare eye tumor of childhood that arises in the retina.
  • Sixty per cent of retinoblastomas are unilateral and most of these forms are not hereditary (median age at diagnosis two years).
  • Retinoblastoma is bilateral in 40% of cases (median age at diagnosis one year).
  • Hereditary retinoblastoma constitutes a cancer predisposition syndrome: a subject constitutionally carrying an RB1 gene mutation has a greater than 90% risk of developing retinoblastoma but is also at increased risk of developing other types of cancers.
  • Diagnosis is made by fundoscopy.
  • Ultrasound, magnetic resonance imaging (MRI) and computed tomography (CT) scans may contribute to diagnosis.
  • Enucleation is still often necessary in unilateral disease; the decision for adjuvant treatment is taken according to the histological risk factors.
  • Conservative treatment for at least one eye is possible in most of the bilateral cases.
  • It includes laser alone or combined with chemotherapy, cryotherapy and brachytherapy.
  • The indication for external beam radiotherapy should be restricted to large ocular tumors and diffuse vitreous seeding because of the risk of late effects, including secondary sarcoma.
  • [MeSH-major] Retinal Neoplasms / diagnosis. Retinal Neoplasms / therapy. Retinoblastoma / diagnosis. Retinoblastoma / therapy
  • [MeSH-minor] Child, Preschool. Diagnosis, Differential. Eye Diseases / diagnosis. Female. Humans. Infant. Pregnancy. Prenatal Diagnosis / methods. Prognosis. Rare Diseases. Retinoblastoma Protein / genetics

  • Genetic Alliance. consumer health - Retinoblastoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Ophthalmol. 2001 Jan;119(1):41-8 [11146725.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Mar;22(3):499-504 [11237973.001]
  • [Cites] Ophthalmology. 2001 Nov;108(11):2116-21 [11713089.001]
  • [Cites] Br J Ophthalmol. 2002 Jan;86(1):80-3 [11801509.001]
  • [Cites] Ophthalmology. 2002 Jun;109(6):1130-6 [12045055.001]
  • [Cites] Arch Ophthalmol. 2002 Jul;120(7):923-31 [12096963.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10):2019-25 [12743157.001]
  • [Cites] Med Pediatr Oncol. 2003 Jul;41(1):36-43 [12764741.001]
  • [Cites] Am J Ophthalmol. 2004 Jan;137(1):18-23 [14700639.001]
  • [Cites] Hum Mutat. 2004 Feb;23(2):193-202 [14722923.001]
  • [Cites] Eur J Cancer. 2004 Jul;40(10):1522-9 [15196536.001]
  • [Cites] Br J Ophthalmol. 2004 Aug;88(8):1069-73 [15258027.001]
  • [Cites] AJR Am J Roentgenol. 2004 Aug;183(2):505-11 [15269048.001]
  • [Cites] Proc Natl Acad Sci U S A. 1971 Apr;68(4):820-3 [5279523.001]
  • [Cites] Ophthalmology. 1999 Oct;106(10):1947-50 [10519590.001]
  • [Cites] Cell Cycle. 2004 Jul;3(7):952-9 [15190215.001]
  • [Cites] Retina. 2004 Dec;24(6):828-48 [15579980.001]
  • [Cites] Ophthalmol Clin North Am. 2005 Mar;18(1):41-53, viii [15763190.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2272-9 [15800318.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Jul;43(3):294-301 [15834944.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1433-40 [15941952.001]
  • [Cites] J Fr Ophtalmol. 2005 Sep;28(7):725-31 [16208222.001]
  • [Cites] Pediatr Blood Cancer. 2006 Jun;46(7):755-61 [16003734.001]
  • [Cites] Ophthalmology. 1998 Aug;105(8):1442-7 [9709755.001]
  • [Cites] Radiol Clin North Am. 1998 Nov;36(6):1101-17 [9884691.001]
  • [Cites] Br J Ophthalmol. 1998 Oct;82(10):1154-8 [9924303.001]
  • [Cites] Hum Gene Ther. 1999 Feb 10;10(3):441-8 [10048396.001]
  • [Cites] Clin Genet. 1999 Jun;55(6):478-82 [10450867.001]
  • [Cites] J Clin Oncol. 1999 Jun;17(6):1829-37 [10561222.001]
  • [Cites] J Clin Oncol. 1999 Jun;17(6):1847-50 [10561224.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):12-7 [10623688.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Aug;28(4):370-9 [10862045.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(15):2881-7 [10920136.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):4010-6 [11051250.001]
  • [Cites] Med Pediatr Oncol. 1980;8(4):397-401 [7453671.001]
  • [Cites] Br J Ophthalmol. 1985 Oct;69(10):742-8 [4052359.001]
  • [Cites] Nature. 1986 Oct 16-22;323(6089):643-6 [2877398.001]
  • [Cites] Ophthalmic Paediatr Genet. 1987 Jun;8(2):95-9 [3658344.001]
  • [Cites] Photochem Photobiol. 1987 Nov;46(5):919-23 [3441513.001]
  • [Cites] J Natl Cancer Inst. 1993 Jul 21;85(14):1121-8 [8320741.001]
  • [Cites] Int Ophthalmol Clin. 1993 Summer;33(3):101-5 [8407173.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 1;29(4):729-33 [8040018.001]
  • [Cites] Hum Mol Genet. 1995 Mar;4(3):383-8 [7795591.001]
  • [Cites] Ophthalmic Genet. 1995 Sep;16(3):109-12 [8556279.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1532-6 [8622068.001]
  • [Cites] J Pediatr Hematol Oncol. 1996 May;18(2):130-4 [8846123.001]
  • [Cites] Am J Hum Genet. 1996 May;58(5):940-9 [8651278.001]
  • [Cites] Cancer. 1996 Mar 15;77(6):1206-13 [8635145.001]
  • [Cites] Arch Ophthalmol. 1996 Nov;114(11):1339-43 [8906024.001]
  • [Cites] Arch Ophthalmol. 1996 Nov;114(11):1348-56 [8906025.001]
  • [Cites] Br J Cancer. 1997;75(1):54-61 [9000598.001]
  • [Cites] JAMA. 1997 Oct 15;278(15):1262-7 [9333268.001]
  • [Cites] Ophthalmology. 1998 Apr;105(4):573-9; discussion 579-80 [9544627.001]
  • [Cites] Eur J Cancer. 1997 Dec;33(14):2368-75 [9616283.001]
  • [Cites] Hum Mutat. 1999;14(4):283-8 [10502774.001]
  • (PMID = 16934146.001).
  • [ISSN] 1750-1172
  • [Journal-full-title] Orphanet journal of rare diseases
  • [ISO-abbreviation] Orphanet J Rare Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Retinoblastoma Protein
  • [Number-of-references] 56
  • [Other-IDs] NLM/ PMC1586012
  • [General-notes] NLM/ Original DateCompleted: 20070719
  •  go-up   go-down


34. Charif Chefchaouni M, Belmekki M, Hajji Z, Tahiri H, Amrani R, El Bakkali M, Msefer Alaoui F, Berraho A: [Ophthalmic manifestations of acute leukemia]. J Fr Ophtalmol; 2002 Jan;25(1):62-6
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Manifestations ophtalmologiques des leucémies aiguës.
  • These lesions are treated as a central nervous system lesion; therefore diagnosis is essential to therapeutic adjustment.
  • The hemogram and myelogram showed a granulocytic sarcoma.
  • Prophylaxis consists of intrathecal injection of methotrexate and reinforcement of chemotherapy.
  • Two years after diagnosis of the ocular lesions, only 1 of the children studied remains alive.
  • [MeSH-major] Eye Diseases / etiology. Leukemia / complications

  • MedlinePlus Health Information. consumer health - Eye Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11965121.001).
  • [ISSN] 0181-5512
  • [Journal-full-title] Journal français d'ophtalmologie
  • [ISO-abbreviation] J Fr Ophtalmol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


35. Biswas J, Madhavan HN, George AE, Kumarasamy N, Solomon S: Ocular lesions associated with HIV infection in India: a series of 100 consecutive patients evaluated at a referral center. Am J Ophthalmol; 2000 Jan;129(1):9-15
HIV InSite. treatment guidelines - Ophthalmic Manifestations of HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To document the ocular disorders seen in patients known to be infected with human immunodeficiency (HIV) virus at a referral eye clinic in India.
  • METHODS: The first 100 individuals known to be HIV-positive at a referral eye clinic between 1993 and 1998 were enrolled in a prospective study.
  • The prevalence of CMV retinitis and HIV retinopathy is lower in India, and there have been no cases of ocular Kaposi sarcoma.
  • The nonavailability and cost of therapy influenced the visual prognosis in these patients.
  • [MeSH-major] Eye Infections, Viral / epidemiology. HIV Infections / epidemiology
  • [MeSH-minor] AIDS-Related Opportunistic Infections / drug therapy. AIDS-Related Opportunistic Infections / economics. AIDS-Related Opportunistic Infections / epidemiology. Adolescent. Adult. Anti-HIV Agents / economics. Anti-HIV Agents / therapeutic use. Child. Child, Preschool. Female. Humans. India / epidemiology. Infant. Male. Middle Aged. Prevalence. Referral and Consultation. Risk Factors

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10653406.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  •  go-up   go-down


36. Al-Jamal KT, Al-Jamal WT, Akerman S, Podesta JE, Yilmazer A, Turton JA, Bianco A, Vargesson N, Kanthou C, Florence AT, Tozer GM, Kostarelos K: Systemic antiangiogenic activity of cationic poly-L-lysine dendrimer delays tumor growth. Proc Natl Acad Sci U S A; 2010 Mar 02;107(9):3966-71
NCI caNanoLab Data Portal. supplemental materials - caNanoLab samples curated from the publication .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The PLL-dendrimer-inhibited tubule formation of SVEC4-10 murine endothelial cells and neovascularization in the chick embryo chick chorioallantoic membrane (CAM) assay.
  • Reduced vascularization of P22 rat sarcoma implanted in the dorsal window chamber of SCID mice was observed following tail vein administration (i.v.) of the PLL dendrimers.
  • Enhanced apoptosis/necrosis within tumors of PLL-dendrimer-treated animals only and reduction in the number of CD31 positive cells were observed in comparison to protamine treatment.
  • This study suggests that PLL-dendrimer molecules can exhibit a systemic antiangiogenic activity that may be used for therapy of solid tumors, and in combination with their capacity to carry other therapeutic or diagnostic agents may potentially offer capabilities for the design of theranostic systems.
  • [MeSH-major] Angiogenesis Inhibitors / pharmacology. Cell Division / drug effects. Dendrimers. Neoplasms, Experimental / pathology. Polylysine / pharmacology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Drugs. 1999 Sep;10(8):767-76 [10573209.001]
  • [Cites] Mol Pharm. 2009 Sep-Oct;6(5):1562-72 [19588994.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2001 Jun;21(6):943-8 [11397701.001]
  • [Cites] Bioorg Med Chem Lett. 2002 Mar 25;12(6):951-4 [11959001.001]
  • [Cites] Acad Radiol. 2002 Aug;9 Suppl 2:S511-3 [12188324.001]
  • [Cites] J Am Chem Soc. 2002 Nov 27;124(47):14137-46 [12440912.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6831-6 [12460895.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2003 Jan;284(1):H215-24 [12388259.001]
  • [Cites] Mol Cancer Ther. 2003 Apr;2(4):419-26 [12700286.001]
  • [Cites] Int J Cancer. 2003 Jun 20;105(3):419-29 [12704680.001]
  • [Cites] Methods Find Exp Clin Pharmacol. 2003 Apr;25(3):215-24 [12743627.001]
  • [Cites] Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S127-33 [14508090.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):2179-89 [15041739.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] Nat Biotechnol. 2004 Aug;22(8):977-84 [15258595.001]
  • [Cites] Exp Eye Res. 2004 Oct;79(4):525-35 [15381036.001]
  • [Cites] Ann Surg. 1972 Mar;175(3):409-16 [5077799.001]
  • [Cites] J Exp Med. 1980 Oct 1;152(4):931-44 [7420025.001]
  • [Cites] Nature. 1982 May 27;297(5864):307-12 [6176876.001]
  • [Cites] Science. 1987 Jan 23;235(4787):442-7 [2432664.001]
  • [Cites] J Invest Dermatol. 1989 Aug;93(2 Suppl):59S-61S [2754280.001]
  • [Cites] Cancer Res. 1992 Dec 1;52(23):6553-60 [1384965.001]
  • [Cites] Lab Invest. 1992 Oct;67(4):519-28 [1279270.001]
  • [Cites] N Engl J Med. 1995 Dec 28;333(26):1757-63 [7491141.001]
  • [Cites] Am J Pathol. 1996 Jul;149(1):59-71 [8686763.001]
  • [Cites] Angiogenesis. 2004;7(2):133-41 [15516834.001]
  • [Cites] Adv Drug Deliv Rev. 2005 Jan 2;57(1):135-52 [15518926.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5317-24 [15958579.001]
  • [Cites] Gene Ther. 2005 Nov;12(21):1544-50 [16034458.001]
  • [Cites] Adv Drug Deliv Rev. 2005 Dec 14;57(15):2177-202 [16310284.001]
  • [Cites] Mol Pharm. 2006 Sep-Oct;3(5):614-27 [17009860.001]
  • [Cites] J Drug Target. 2006 Jul;14(6):405-12 [17092840.001]
  • [Cites] J Control Release. 2006 Dec 1;116(3):330-6 [17118476.001]
  • [Cites] Biochem Soc Trans. 2007 Feb;35(Pt 1):61-7 [17233602.001]
  • [Cites] Nat Rev Drug Discov. 2007 Apr;6(4):273-86 [17396134.001]
  • [Cites] Clin Cancer Res. 2007 Jun 1;13(11):3395-402 [17545548.001]
  • [Cites] Mol Cancer Ther. 2008 Dec;7(12):3670-84 [19074844.001]
  • [Cites] Mol Pharm. 2009 Jul-Aug;6(4):1190-204 [19453158.001]
  • [Cites] Carcinogenesis. 2000 Mar;21(3):505-15 [10688871.001]
  • (PMID = 20150514.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / 9993
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Cations; 0 / Dendrimers; 25104-18-1 / Polylysine
  • [Other-IDs] NLM/ PMC2840079
  •  go-up   go-down


37. Coral S, Sigalotti L, Altomonte M, Engelsberg A, Colizzi F, Cattarossi I, Maraskovsky E, Jager E, Seliger B, Maio M: 5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Clin Cancer Res; 2002 Aug;8(8):2690-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Limited therapeutic options are presently available for advanced renal cell carcinoma (RCC).
  • This study was designed to define the clinical potential of the DNA hypomethylating agent 5-aza-2'-deoxycytidine (5-AZA-CdR) in human RCC, through its control of the expression of "therapeutic targets" of the cancer testis antigen (CTA) family, and of the tumor-associated antigen RAGE-1, in RCC cells.
  • De novo expression of NY-ESO-1 was persistent, being still detectable 60 days after the end of treatment, and generated a functional protein efficiently recognized by HLA-A2-restricted NY-ESO-1-specific CTLs.
  • 5-AZA-CdR also induced RAGE-1 expression in RAGE-1-negative RCC and sarcoma cells but not in neoplastic cells of different histology.
  • [MeSH-major] Antigens, Neoplasm / biosynthesis. Antimetabolites, Antineoplastic / pharmacology. Azacitidine / analogs & derivatives. Azacitidine / pharmacology. Carcinoma, Renal Cell / drug therapy. Immunotherapy / methods. Kidney Neoplasms / drug therapy. Membrane Proteins
  • [MeSH-minor] Antibodies, Monoclonal. Blotting, Western. Electrophoresis, Polyacrylamide Gel. Eye Proteins / biosynthesis. Humans. Melanoma-Specific Antigens. Mitogen-Activated Protein Kinases. Neoplasm Proteins / biosynthesis. Precipitin Tests. Protein Biosynthesis. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Time Factors. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12171902.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Antimetabolites, Antineoplastic; 0 / CTAG1B protein, human; 0 / Eye Proteins; 0 / MAGEA1 protein, human; 0 / MAGEA3 protein, human; 0 / Melanoma-Specific Antigens; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 776B62CQ27 / decitabine; EC 2.7.11.22 / MOK protein, human; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; M801H13NRU / Azacitidine
  •  go-up   go-down


38. Lo M, Wang YZ, Gout PW: The x(c)- cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases. J Cell Physiol; 2008 Jun;215(3):593-602
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The x(c)- cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases.
  • In the past decade it has become evident that the x(c) (-) transporter plays an important role in various aspects of cancer, including: (i) growth and progression of cancers that have a critical growth requirement for extracellular cystine/cysteine, (ii) glutathione-based drug resistance, (iii) excitotoxicity due to excessive release of glutamate, and (iv) uptake of herpesvirus 8, a causative agent of Kaposi's sarcoma.
  • The x(c) (-) transporter also plays a role in certain CNS and eye diseases.
  • This review focuses on the expression and function of the x(c) (-) transporter in cells and tissues with particular emphasis on its role in disease pathogenesis.
  • [MeSH-major] Amino Acid Transport Systems / metabolism. Antiporters / metabolism. Cystine / metabolism. Glutamic Acid / metabolism. Neoplasms / therapy

  • Hazardous Substances Data Bank. GLUTAMIC ACID HYDROCHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [CommentIn] J Cell Physiol. 2009 Aug;220(2):531-2; author reply 533-4 [19415694.001]
  • (PMID = 18181196.001).
  • [ISSN] 1097-4652
  • [Journal-full-title] Journal of cellular physiology
  • [ISO-abbreviation] J. Cell. Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amino Acid Transport Systems; 0 / Antiporters; 3KX376GY7L / Glutamic Acid; 48TCX9A1VT / Cystine
  • [Number-of-references] 177
  •  go-up   go-down


39. Ayena KD, Amedome KM, Agbo AR, Kpetessou-Ayivon AL, Dzidzinyo BK, Djagnikpo PA, Banla M, Balo KP: [Ocular manifestations in HIV/AIDS patients undergoing highly active antiretroviral treatment (HAART) in Togo]. Med Trop (Mars); 2010 Apr;70(2):137-40
HIV InSite. treatment guidelines - Ophthalmic Manifestations of HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ocular manifestations in HIV/AIDS patients undergoing highly active antiretroviral treatment (HAART) in Togo].
  • AIM: The twofold purpose of this study in people living with human immunodeficiency virus (PLHIV/AIDS) and undergoing highly active antiretroviral treatment (HAART) was to determine the prevalence of ocular manifestations and its correlation with CD4 T-cell count.
  • CD4 T-cell counts and use of antiretroviral treatment was noted.
  • A thorough eye examination was performed in all cases.
  • One case of palpebral and conjunctival Kaposi's sarcoma was noted.
  • The most common type of posterior segment involvement was cotton-wool nodules (35.5%).
  • [MeSH-major] Acquired Immunodeficiency Syndrome / drug therapy. Antiretroviral Therapy, Highly Active / adverse effects. Conjunctivitis / chemically induced. Eye Infections / chemically induced. HIV Infections / drug therapy. Herpes Zoster / etiology


40. Rzepecki P, Barzal J, Sarosiek T, Oborska S, Szczylik C: How can we help patients with refractory chronic graft versus host disease- single centre experience. Neoplasma; 2007;54(5):431-6
Genetic Alliance. consumer health - Chronic Graft versus Host Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ocular involvement as well as dermal sclerosis, joint contractures and pathological changes in oral cavity are often refractory to treatment.
  • This kind of patients require complex aggressive immunosuppressive therapy.
  • We are still waiting for drugs against cGVHD, characterized by decreased infectious complications, encouraging efficacy and rare and reversible side effects.
  • We describe eight patients who developed extensive chronic graft versus host disease with eye involvement after alloHSCT.
  • All had ocular manifestations, which were refractory to the first and second line of systemic immunosuppressive therapy.
  • All patients responded to the topical cyclosporine therapy, but clinical improvement was seen only since the fifth month of starting treatment.
  • Other four patients with sclerodermoid type of skin changes, refractory to second line systemic immunosuppressive therapy, were treated with clofazimine.
  • Clofazimine is a drug used to treat leprosy.
  • Because of its anti-inflammatory effects, clofazimine is used also as a second or third line therapy for various skin disorders including: pyoderma gangrenosum, lupus erythematosus, palmoplantar pustulosis and chronic graft versus host disease.
  • All patients,who received clofazimine due to dermal sclerosis, joint contractures and oral manifestations, achieved partial or complete responses and were able to reduce other immunosuppressive drugs.
  • [MeSH-major] Graft vs Host Disease / drug therapy. Hematopoietic Stem Cell Transplantation / adverse effects. Leukemia, Myeloid / therapy. Sarcoma, Myeloid / therapy
  • [MeSH-minor] Adult. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Chronic Disease. Clofazimine / therapeutic use. Female. Humans. Male. Middle Aged. Transplantation, Homologous / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17688373.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; D959AE5USF / Clofazimine
  •  go-up   go-down


41. Urtti A, Polansky J, Lui GM, Szoka FC: Gene delivery and expression in human retinal pigment epithelial cells: effects of synthetic carriers, serum, extracellular matrix and viral promoters. J Drug Target; 2000;7(6):413-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Non-viral gene therapy is a potential treatment to many incurable retinal diseases.
  • In RPE cells, Rous sarcoma virus and cytomegalovirus (CMV) were more efficient promoters than SV40 in driving luciferase expression, and CMV was chosen for further experiments.
  • Despite low percentage of transfected cells the transgene expression per RPE cell is high, important feature in the retinal tissue with small dimensions, in particular in the case of secreted gene products.
  • [MeSH-major] Extracellular Matrix / physiology. Genetic Therapy. Pigment Epithelium of Eye / metabolism

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10758912.001).
  • [ISSN] 1061-186X
  • [Journal-full-title] Journal of drug targeting
  • [ISO-abbreviation] J Drug Target
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK-46052; United States / NEI NIH HHS / EY / EY 02162; United States / NEI NIH HHS / EY / EY 02477
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] SWITZERLAND
  • [Chemical-registry-number] 0 / Liposomes; 0 / Polymers; EC 1.13.12.- / Luciferases
  •  go-up   go-down


42. Roels P: Ocular manifestations of AIDS: new considerations for patients using highly active anti-retroviral therapy (HAART). Optometry; 2004 Oct;75(10):624-8
HIV InSite. treatment guidelines - Ophthalmic Manifestations of HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ocular manifestations of AIDS: new considerations for patients using highly active anti-retroviral therapy (HAART).
  • BACKGROUND: Highly active anti-retroviral therapy (HAART) effectively restores the immune system and lowers the viral load in patients with human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS).
  • Since widespread use of HAART drugs began in 1996, many AIDS patients are living longer and enjoying a higher quality of life.
  • HAART and immune recovery is now considered the preferred treatment for CMV retinitis.
  • Incidence of Kaposi's sarcoma has declined by an estimated 87% and molluscum contagiosum is seen less frequently in those using HAART.
  • [MeSH-major] AIDS-Related Opportunistic Infections / drug therapy. Antiretroviral Therapy, Highly Active. Cytomegalovirus Retinitis / drug therapy
  • [MeSH-minor] Antiviral Agents / therapeutic use. Humans

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15508863.001).
  • [ISSN] 1529-1839
  • [Journal-full-title] Optometry (St. Louis, Mo.)
  • [ISO-abbreviation] Optometry
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents
  • [Number-of-references] 29
  •  go-up   go-down






Advertisement